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CHAPTER 1
INTRODUCTION

Central and peripheral nervous tissues embody and direct the motor, sensory and
cognitive experience of all mammals.

Damage to these tissues results in functional

impairment which is only ameliorated upon repair of the damaged area or a shift in function to
an undamaged area.

Central nervous system (CNS) tissue is less adaptable to injury than

peripheral nervous system (PNS) tissue, especially in the adult animal.

While endogenous

repair and remodeling mechanisms are crucial to a favorable prognosis following nervous
tissue injury, exogenous repair aids can, depending on injury type and location, greatly improve
functional outcome.

Such exogenous interventions include the use of drugs, surgery,

stimulation by electrical fields, acupuncture, diet and physical therapy.
Studies in recent times have shown that adrenocorticotropic hormone (ACTH) has
significant neurotrophic properties when administered to rats with experimentally crushed
sciatic nerve e.g. (Strand & Kung, 1980). These effects are enhanced in adrenalectomized
animals. Structure-activity-relationship (SAR) studies reveal that the neurotrophic properties of
the ACTH peptide reside within the first 13 amino acids e.g. (Luneburg & Flohr, 1988). This
same series of studies demonstrated neurotrophic effects of residues 4-7.

A degradation

resistant tri-substituted ACTH4-9 analogue, Org2766, retains the neurotrophic properties of the
parent peptide, but is devoid of corticotropic activity.
The present work describes the development of a cell culture model in which to
investigate the effects of and mechanisms by which Org2766 protects and/or speeds recovery
from damage sustained as a result of chemical insult. The cultures were derived from an
immortalized murine neuroblastoma tumor cell line.
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Three general approaches were taken. In the first, the cultures were exposed to either
vincristine

sulfate,

colchicine

(microtubule

depolymerizing

agents},

cytochalasin

D

(microfilament depolymerizing agent} or A23187 (Ca++ ionophore} in the presence or absence
of graded doses of Org2766. Cell media supernatant was then sampled at 8, 24 and 48 hrs
and assayed for lactate dehydrogenase (LDH} activity.

Extracellular LDH levels rise

concomitant with damage to the cell membrane (or cell death}; therefore, LDH levels were
taken to correlate positively with toxic damage. The neurotrophic effects of Org2766 in this
experiment result in reduced LDH activity relative to control conditions. A positive finding in
the first experiment prompted a study to determine whether Org2766 could modulate the rate
of de novo protein synthesis.

Cultures were pulsed with 35S-methionine in the presence or

absence of graded doses of Org2766 for 60 min. Protein synthetic rates were then calculated
from the combined results of total protein determined by the method of Lowry and a scintillation
count to measure incorporation of the labeled methionine. Org2766 was found to stimulate
protein synthesis in a dose-dependent fashion with 1o-8 M representing an optimal dose. The
final approach utilized time-lapse video microscopy to measure morphological recovery of the
cultured cells following colchicine insult under various Org2766 treatment conditions.

Cells

recovered more rapidly when treated with Org2766 irrespective of whether the peptide was
administered before, during or after colchicine treatment.
At present, neither the in vivo nor in vitro neuroprotective mechanism(s} of action of
Org2766 are known. The studies described here do show that the peptide can exert trophic
effects directly on nerve-like cells in culture. This suggests that a primary in vivo neurotrophic
action may be directed at neurons, but does not rule out concomitant effects mediated by glial
cells.

CHAPTER II
LITERATURE REVIEW

Non-hormonal Activities of ACTH and Fragments
Source of ACTH and a-MSH

Adrenocorticotropin [ACTH] and a-melanocyte stimulating hormone (a-MSH] are pituitary
released peptides, with the latter consisting of the first 13 amino acids of the 39 amino acid
ACTH molecule. ACTH is derived from the parent pro-opio-melanocortin peptide (Mains et al.,
1977). In addition to their known corticotropic and melanotropic activities, both have been shown
to exert tropic and trophic effects on mammalian PNS and CNS tissues, a topic of this review.

Early Evidence for ACTH Effects on CNS Tissue

As early as the 1950's, ACTH was shown to promote axonal regeneration in the spinal cord
of the cat and dog (Windle & Chambers, 1950) and was thought to mimic the effects of Piromen
(Windle et al., 1952b), a potent pyrogenic bacterial polysaccharide, which some claimed could
enhance CNS regeneration.

Piromen stimulates release of large quantities of pituitary

hormones, including ACTH (Chambers et al., 1949). The resultant high levels of circulating
adrenal corticoids were thought to reduce glial scarring (Oppenheimer & Reister, 1954), thus
enhancing CNS axon regeneration (Windle et al., 1952a). More recent studies have failed to
confirm these early findings regarding the stimulation of CNS regeneration by ACTH or Piromen
(e.g. McMasters, 1962). Note that these unconfirmed early studies, however, were performed on
animals with intact adrenals. Despite their shortcomings, these studies provided a rationale for
performing additional studies on the effects of ACTH and derivatives on a number of behavioral
and biochemical indices.
3
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ACTH Behavioral Effects
In a seminal study, adenohypophysectomized male rats were trained in a one-way active
avoidance shuttlebox task (De Wied, 1964).

Those animals receiving sufficient ACTH

replacement performed conditioned avoidance response behaviors at a level indistinguishable
from sham-operated rats. Similarly, ACTH improved escape latency in a noxious stimuli runway
task in the same set of experiments. This is one of the first published works demonstrating the
involvement of ACTH in learning and behavior since the work of Mirsky (Mirsky et al., 1953).
The behavioral effects of ACTH are not dependent on the adrenal hormones as ACTH has
similar effects in adrenalectomized animals when measuring extinction of conditioned avoidance
behaviors (Miller & Ogawa, 1962).
Structure-activity-relation (SAR) studies are crucial in the determination of the minimal
peptide sequence necessary for induction of the behavioral effects of ACTH.

ACTH 1_16 is

sufficient to produce corticotrophic activity of the ACTH 1_39 molecule. Increasing peptide length
from 17 to 23 residues only increases the potency of the molecule. Since the behavioral effects
are not mediated via adrenal hormones, it was thought the behavioral effects might require less
than the entire 39 residue sequence.

Minimal ACTH ·sequence for Behavioral Activity
A series of experiments were performed, using male rats, to assess the minimal peptide
sequence necessary to facilitate acquisition and extinction performance in a variety of behavioral
paradigms as reviewed by De Wied (Greven & De Wied, 1973). All peptides were administered
subcutaneously (s.c.). Dosing quantities and schedules were experiment-dependent.
Avoidance acquisition was tested in both a one-way shuttlebox (De Wied, 1964) (active
avoidance) and a one-trial (passive) avoidance paradigm (Ader et al., 1972). The animals in the
shuttlebox experiment were hypophysectomized and allowed to recover from the surgery prior to
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testing. The peptides were administered on alternate days in the active avoidance experiment
and as a single injection 1 h before the passive avoidance test.
Extinction trials were begun in the shuttlebox experiment after each rat had achieved a
criterion of 80% or better avoidance responses for 3 consecutive days. Extinction trials were
performed identically to the acquisition phase minus the footshock unconditioned stimulus (UCS)
and the visible light conditioned stimulus (CS) was terminated after 5 sec in the absence of an
avoidance response. Trials to extinction were also measured following training to criterion in an
active avoidance pole-jump experiment in which the rat was presented with a CS (light) and then
received a shock via the grid floor if the avoidance response 0umping onto and grasping a
vertical pole) diq not occur within 5 sec (De Wied, 1966). The pole-jump extinction trials were
identical to the acquisition trials minus the footshock UCS. Only a single peptide injection 1 h
prior to beginning of extinction was used in the pole-jump experiment.
Drug treatment conditions for the shuttlebox experiment were ACTH 1_39 , ACTH 1_24, a.MSH (residues 1-13 of ACTH), ACTH 1_10, ~-MSH (ACTH 1_18 plus the 3 amino acids preceding
position 1), ACTH4- 10, sham-operated placebo and hypophysectomized placebo.

All peptide

conditions resulted in similar avoidance acquisition scores relative to sham-operated placebo
conditions, with all scores roughly three times higher than hypophysectomized control animals.
In the experiment measuring extinction of shuttlebox avoidance behavior the peptides
studied were ACTH 1_39 (1.5 1.U.), a-MSH (6 µg), ACTH 1_10 (10 µg), ~-MSH (6 µg) and ACTH4- 10
(20 µg), all doses s.c.

Avoidance behaviors took roughly twice as many trials to extinction in

the peptide vs. saline condition (more trials to extinction is interpreted as an adaptive behavior in
this paradigm).
The dosing and peptide regimen for the extinction of pole-jumping response experiment
were ACTH 1_39 (3 1.U.), ACTH 1_24 (10 µg), a-MSH (6 µg), ACTH 1_10 (10 µg), ACTH 11 _24 (10 µg),
~-MSH (6 µg), ACTH4-10 (20 µg) and saline control. Only ACTH 11 _24 was ineffective in delaying
extinction vs. control condition. Only four ACTH fragments were tested in the passive avoidance
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test, 30 µg each of ACTH 1_10 , ACTH 11 _24 , ACTH25-39 and ACTH4-10, as well as a saline control.
Fragments 1-10 and 4-10 resulted in longer latencies relative to control, while 11-24 and 25-39
did not.
In the experiments described above only those peptides sharing a common core of
residues 4-10 were effective in altering behavior relative to control. This relationship between
peptide length and behavioral (biological) activity was studied in a more systematic fashion to
determine the minimum sequence retaining the ability to enhance performance on the extinction
of a pole-jumping avoidance response and on the response latency of a passive avoidance task
(Greven & De Wied, 1967).

The sequences looked at were

ACTH 1 _ 10 ⇒ACTH 7 _ 10

with the

shortening taking place one residue at a time from the amino-terminus. ACTH4- 10 was shown to
be the shortest fragment that retains behavioral effects on these tasks with a potency similar to
that of the parent molecule. A follow-up experiment by the same group shortened ACTH4-10 one
residue at a time from the carboxy-terminus. ACTH4-7 was shown to be the shortest fragment
with behavioral effects. Slightly higher doses, however, were required to equal the effects of
ACTH4-10.
The studies outlined above led researchers to search for ACTH analogues more
efficacious with greater potency. One such analogue with a potency three magnitudes greater
than that of ACTH4- 10 is a tri-substituted ACTH4-9 analogue (later manufactured by Organon,
International [Org2766]). The sequences of the two peptides are as follows:
ACTH 4 _10 : Met-Glu-His-Phe-Arg-Trp-Gly
Org2766 : Met(02 )-Glu-His-Phe-D-Lys-Phe

The potent behavioral effects of ACTH fragments led workers to more directly test for the
involvement of CNS structures in the activity of these peptides.

ACTH Fragments Affect CNS Protein Synthesis

Male, hypophysectomized rats were treated with 20 µg s.c. of either ACTH 1_10-7-L-Phe,
ACTH 1_10-7-D-Phe or ACTH 11 _24 as a long-lasting zinc-phosphate preparation or saline every
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other day for 12 days beginning 5 days post-surgery

(Schotman et al., 1972). Radioactive

incorporation experiments were performed following the last peptide treatment by injection of 20
µCi of [2- 14C]-uridine or 20 µCi of [4,5- 3H]-leucine into the diencephalon to measure RNA and
protein synthesis, respectively. Animals were sacrificed either 70 min after uridine injection or 5
min after leucine injection.

ACTH 1_10-7-L-Phe had no effect on rapid uridine incorporation;

whereas, a 28%. increase in rapidly labeled protein was observed. A 28% decrease in protein
synthesis was observed when treated with ACTH 1_10-7-D-Phe. This is an interesting result in
light of the finding that these two peptides exert opposite effects in an extinction of avoidance
behavior paradigm (Bohus & De Wied, 1966); specifically, increased protein synthesis positively
correlates with an inhibitory effect and the D-isomer peptide, which decreases protein synthesis,
correlates with a facilitation of extinction of avoidance behaviour. Consistent with this finding,
ACTH 11 _24 which does not have behavioral activity, had no effect on protein or RNA synthesis.
Neither of the ACTH 1_10 analogues modulated RNA metabolism. These results are consistent
with the idea that the behavioral effects of ACTH-like analogues are mediated via a translational
vs. a transcriptional mechanism. The labeling kinetics of nuclear vs. cytoplasmic protein were
also determined in this study. The labeled protein in the nuclear fraction was associated with
ribosomes attached to the outer nuclear membrane suggesting that the newly synthesized
protein in the nuclear and soluble cytoplasmic fraction are the same.
A follow-up study (Reith et al., 1974) looked at the in vitro effects of ACTH 1_10-7-L-Phe on
brainstem slices obtained from hypophysectomized male rats. Drug protocols were similar to
those described previously.

First, hypophysectomy resulted in a 30% decline in [U- 14C]-Leu

incorporation vs. sham-operated controls.

Peptide treatment reversed this decline at sub-

nanomolar doses with a 39% increase seen at 1o-5 M. These results are further evidence for a
direct action of ACTH-like peptides on brain structures.

A similar in vitro study compared

ACTH 1_24, ACTH 11 _24 , ACTH 1_10-7-L-Phe and ACTH 1_10-7-D-Phe vs. control on labeled leucine
incorporation into rat brainstem slices obtained from hypophysectomized rats. Consistent with
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previous findings ACTH 1_24 and ACTH 1_10-7-L-Phe stimulated leucine incorporation while
ACTH 1_10-7-D-Phe decreased and ACTH 11 _24 had no effect on protein synthesis (Reith et al.,
1975).

The administration of ACTH or ~-MSH, i.p., increases protein synthesis in mouse
cerebrum, cerebellum, pons and medulla by 20 to 100% at 6, 12 and 24, but not 3, hrs postadministration (Rudman et al., 1974).

No effects on protein synthesis were observed in

thalamus, hypothalamus, liver, kidney, striated muscle or spleen. Uptake of [U- 14CJ-leucine into
brain stem slices taken from hypophysectomized versus sham-operated controls demonstrate a
30% decrease in labeled protein (Reith et al., 1974). This decline could be due to the loss of
endogenous ACTH and ACTH-derived peptides.

ACTH and Fragments Affect Cyclic Nucleotide Metabolism in CNS

Early reports showed no effect of ACTH on adenylate cyclase activity in cell-free
membrane preparations (Burkhard & Gey, 1968; Von Hungen & Roberts, 1973) or on cAMP
accumulation in rat cerebral cortex slices (Forn & Krishna, 1971).

However, intrathecal

injections of µg amounts of ACTH or ~-MSH increased cAMP, but not cGMP, levels in rabbit
cerebrospinal fluid (CSF) 30-120 min post-injection (Rudman, 1976). Obviously, the source of
the cAMP remains obscure in the in vivo study. In a follow-up study they showed that ACTH 1_24,
~-MSH and a-MSH stimulate the in vitro production and accumulation of cAMP in the choroid
plexus of the lateral, 3rd and 4th ventricles, pineal gland, sub-commissural organ and the area
postrema (Rudman, 1978). Rats chronically treated with a-MSH show elevated levels of cAMP
in occipital cortex of both intact and hypophysectomized animals (Christensen et al., 1976).
Chronic a-MSH had no effect on cGMP in rat CNS of intact animals, but did raise cGMP in the
thalamus of hypophysectomized rats (Spirtes et al., 1978).
ACTH 1_24 stimulates adenylate cyclase activity at 1 and 1O µM, but inhibits the enzyme at
higher concentrations in a CNS sub-cortical broken cell preparation. In the same study, cAMP
levels were shown to peak between 5 and 10 min post-ACTH 1_24 in rat striatal slices with levels
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gradually descending towards control levels after 1O min (Wiegant & Gispen, 1975). No effects
on cAMP concentrations were observed in other brain regions. These results cannot be taken as
evidence that the cAMP second messenger system(s) mediate all or any of the neurotrophic
properties of N-terminal ACTH fragments, but only suggest a possible role for cAMP.
Interestingly, the cAMP-sensitive phosphoprotein GAP-43 (also known as B-50 and F1),
which at the cellular level stains most heavily in synaptic regions (Gispen et al., 1985), but is
ubiquitous at the whole-brain level and is important in synaptic development and maintenance, is
indirectly sensitive to ACTH fragments through the adenylate cyclase pathway (Matus et al.,
1976). Those ACTH fragments which are effective in stimulating phosphorylation of GAP-43
also induce excessive grooming behavior in the rat (Gispen & Isaacson, 1980).

Similarly,

ACTH 1_24 stimulated the incorporation of 32P into rat brain synaptosomal plasma membranes in
a biphasic fashion. Millimolar concentrations of ACTH 1_24 decreased 32P incorporation while µM
amounts had no effect and nM concentrations inhibited phosphorylation (Zwiers et al., 1976).
The net phosphorylation measured in the previous study is the combined result of
phosphorylation by protein kinases, dephosphorylation by protein phosphatases and the
depletion of labeled ATP by various ATPases.
Neurotrophic Properties of ACTH

ACTH has been shown to exert neurotrophic effects on dissociated neurons derived from
chick embryo cerebral hemispheres. These neurons grow well in serum-supplemented, but not
serum-free medium. In the absence of serum the cells develop vacuoles, retract their neurites
and begin to fragment.

ACTH prevents these degenerative morphological signs, increases

protein and RNA synthesis and enhances 2-deoxyglucose uptake at ACTH concentrations
ranging from 10-9 to 10-7 M, with 10-a M being optimal for all effects (Daval et al., 1983).
Neurons in the serum-free condition with no ACTH died within one to two days. There is no
ready reason as to why ACTH increases RNA synthesis in this preparation and not those
described previously.
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As stated earlier, the failure of ACTH to induce neurotrophic effects in animal studies may
have been related to the fact that ACTH causes release of steroid hormones produced in the
adrenal glands. The steroids may have countered the neurotrophic properties of ACTH. To test
this hypothesis, the sciatic nerve was unilaterally crushed in adrenalectomized and shamoperated control rats. ACTH treated, adrenalectomized rats recovered sensation and functional
movement sooner than saline controls (Strand & Kung, 1980). Axonal regrowth proceeds at a
faster pace and the number of large endplates and the frequency of preterminal branching
increases. No effect was seen in either intact or denervated muscle.
Low-dose (10-8 M) ACTH4- 10 and ACTH 1_24 increase the density of the neural network,
stimulates formation of neuronal aggregates and enhances neurite fasciculation of embryonic rat
cerebral cells in vitro (Richter-Landsberg et al., 1987). The same study also showed a 30%
increase in acetylcholinesterase activity, with no changes seen in the acid-insoluble protein
fraction.
Neurotrophic and Behavioral Effects of Org2766
Developmental Effects of Org2766

Both spontaneous activity and cold-stress-induced motor activity are increased three to
five-fold in 11 to 13 day old rats following daily treatment with 10 µg/kg Org2766 i.p. (Acker et
al., 1985). These levels of activity are not observed in the saline controls until day 14 or 15.

Such findings are consistent with an acceleration of developmental events as regards motor
behaviors and, presumably, central and peripheral motor systems. Consistent with the above,
1O µg/kg 24 h·1 of Org2766 increases twitch and tetanic tensions in the extensor digitorum longus
(EDL) muscle-peroneal nerve in situ preparation of 15 day old rats (Acker et al., 1986). This
study, however, failed to confirm the increase in spontaneous and cold-evoked behavior seen
earlier by this group (Acker et al., 1985).
Even more direct evidence for an effect of Org2766 on developing motor systems is
provided by an experiment showing an increased number of postjunctional folds and a greater
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endplate area following 0.01 µg/kg/day of sub-cutaneously administered peptide from birth to day
14, at which time scanning electron microscopy was used to examine the neuromuscular junction
(NMJ) (Frischer et al., 1985). These results are interpreted as an acceleration of maturation of
the NMJ. Interestingly, nicotine had a similar effect. Whether the observed effects are primarily
a result of protein synthetic regulation, nerve/muscle electrochemical stimulation or some other
mechanism, is not certain.
Org2766, administered using the same regimen as in the Acker 1985 study, increased
end-plate perimeter and nerve terminal branching during the first seven postnatal days at a dose
of 0.01 µg/kg/day (Frischer & Strand, 1988). Only terminal branching remained elevated relative
to saline control by day 14. No differences in any of the measured parameters was observed by
day 21. These effects are very dose-dependent as 10 µg/kg inhibits nerve terminal sprouting at
7 and 14 days. It is difficult, however, to reconcile the inhibition seen at 1O µg/kg as the 1985
Acker et al. study noted an increase in spontaneous and cold-stress-induced motor activity at the
same dose. Differential CNS effects are likely responsible. The results are of particular interest
as the peptide effects correlate with the critical period for NMJ maturation. The effects stop at
the timepoint corresponding with cessation of polyneuronal innervation of individual muscle
fibres.
These results are consistent with a role for Org2766 in regulation of the development of
the NMJ and perhaps in CNS structures.
Org2766 and PNS Mechanical Injury

Following unilateral crush of the sciatic nerve, female rats were tested for return of
sensorimotor function using a foot-flick paradigm in which a 47°C air stream was applied to the
sole of the foot and latency to retraction was measured.

Three doses of sub-cutaneously

injected Org2766 were used, 0.1, 1.0 and 10.0 µg, in either a long-acting zinc phosphate
(Zn 3(PO,4) 2 )-preparation or the unconjugated peptide every other day for the 18 day duration of
the experiment (Bijlsma et al., 1983). The peptide significantly decreased latency to recovery at
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1 and 10, but not 0.1 µg. Accelerated return of sensorimotor function was observed in 4, 8, 12
and 52 week old animals, but to a lesser extent in the one year rats.

Restriction of peptide

treatment to either the first or last 9 days inhibited the effect, suggesting that sensitivity to
Org2766 is maintained throughout the entire recovery period. Of interest, the three carboxyterminal residues of Org2766 (Phe7-D-Lys8-Phe9) had no effect on recovery. The tripeptide is
the major metabolic product of Org2766 (Witter et al., 1975), suggesting the neurotrophic
properties do not reside exclusively in the carboxyl portion of the peptide. This is mentioned
here as DeWied had noted a facilitating effect of Org2766 on passive avoidance behavior
resides in the (low dose) amino terminal residues, while an inhibition of passive avoidance
learning is induced by the tripeptide carboxy portion (Fekete & DeWied, 1982b).
In the crushed rat sciatic nerve, Org2766 increases the number of outgrowing neurites at
2, 3 and 4 days post-injury following a 1 µg s.c. injection immediately after and again 48 hrs after
the crush (Verhaagen et al., 1987a). The increase in neurite number could be seen 0, 3 and 7
mm distal to the injury site at day 4 suggesting the increase was not solely due to sprouting
occurring at earlier times vs. control.

In the same study a single dose of Org2766 was

administered immediately post-crush at either 0, 0.01, 1 or 100 µg and the number of neurites
was measured at the distal border of the nerve on day 3.

Both 1 and 100 µg doses were

effective in increasing neurite number.
The dosing protocol was also shown to be an important factor, again using the number of
outgrowing neurites as the dependent variable. The results showed 8 µg of Org2766 to be more
effective if administered in two 4 µg injections 48 hrs apart vs. eight 1 µg injection separated by
12 hrs. The Verhaagen results suggest that it is the number of neurites, not the growth rate of
new sprouts, which is affected. The dosing regimen study demonstrates that higher peak blood
levels of Org2766 may be more effective than a more intermittent dosing schedule resulting in
lower peak blood levels. These studies further indicate the importance of testing a range of
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doses over a variety of administration protocols

in order to determine an optimal dose of

Org2766.
Route of peptide administration is also a key factor as regards the efficacy of Org2766.
Using a recovery of sensorimotor function paradigm similar to that of Bijlsma and co-workers
(Bijlsma et al., 1983), young adult female rats were administered Org2766 under the following
protocols:

two daily s.c. injections of 1O µg;

20-40 µg/day

via subcutaneously implanted

osmotic mini-pumps; 40 µg/day delivered by s.c. biodegradable micro-spheres; 1.5-20 mg/day
via peptide dissolved in drinking water or by gavage (Dekker et al., 1987). Direct s.c. injections,
mini-pumps and micro-spheres were equally effective in speeding recovery from sciatic crush.
Neither administration via drinking water nor by gavage were effective.
Confirming the increase in neurite number following peripheral nerve crush in the presence
of Org2766, rats were treated with 1 µg of peptide immediately after sciatic crush and again at
48 hrs (Verhaagen et al., 1987b). Using antibodies against a-MSH which selectively cross-reacts
with the 150 kDa neurofilament protein,

investigators were able to more accurately count

neurites. Light microscopic, even electron microscopic, counting of neurites is difficult .due to
f

their small diameter (<1 µm) and the degenerative debris. Previous results showing an increase
in neurite number were confirmed in this experiment.
Building on these results, the sciatic crush paradigm was performed using a similar dose
regime and neurite counting and recovery of sensorimotor function assays employed 13 days
after crush injury (Tonnaer et al., 1992). The independent variable was modified to include two
types of nerve crush:

1) the standard crush with parallel-grooved forceps;

2) a crush with

forceps having cross-hatched jaws. A positive peptide effect was only seen when the injury was
made with parallel-grooved forceps.

The endoneural tubes (epineurium) and Schwann cells

appeared to receive less damage in this condition. A slightly larger axon diameter was also
observed in the parallel-grooved condition. These results may be suggestive of a direct action of
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Org2766 on Schwann cells as a primary mechanism of action because efficacy appears to
correlate positively with Schwann cell survival.
Van der Zee et al. were able to replicate the return of sensorimotor function results in 6-7
week, 5 mo and 20 mo old rats (Van Der Zee et al., 1991) using 7.5 µg/kg 48 h-1 s.c. Org2766.
This is an important result as they demonstrate that Org2766 can also stimulate regenerative
processes in aged animals . A direct comparison with a-MSH showed Org2766 to be as potent
and as efficacious in accelerating recovery from peripheral nerve damage.
Laryngeal abductor reinnervation surgery was performed on ten cats, half of which
received 25 µg/kg/48 hrs for 30 days prior to surgery.

Both EMG and video-laryngoscopic

recordings showed a trend towards earlier and more complete recovery in the Org2766 group.
Histological evaluation showed no difference in myelin thickness and axon diameter.

Axon

number, however, was 26% higher in the peptide group (Mahieu et al., 1993).
Org2766 can also improve electrophysiological aspects of regenerating rat sciatic nerve
(De Koning & Gispen, 1987).

Functional recovery of sensory and motor

parameters were

accelerated by peptide, but both saline and peptide groups demonstrated complete recovery by 4
weeks.

However, compared to the contra-lateral uncrushed sciatic, motor nerve conduction

velocity (MNCV) measured by the M-reflex, and sensory nerve conduction velocity (SNCV)
measured via the H-reflex, fully recovered in the presence of peptide by 90 and 120 days,
respectively. The saline controls displayed a 20-40% deficit in both MNCV and SNCV as late as
214 days following crush. These results suggest functional measures may lack sensitivity in
detecting recovery differences and that electrophysiological parameters should also be followed.
Org2766 and PNS Chemical Injury: Rat & Human

Cisplatin [cis-diaminedichloroplatinum (II)] has proven an effective drug in the treatment
of ovarian, testicular and bladder carcinomas (Gerhenson et al., 1981). There exists a strong
dose-response relationship between Cisplatin administration and clinical efficacy (Dembo, 1987)
with some reports suggesting that larger doses of Cisplatin would be more effective (Ozols et
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al., 1985).

The development of a largely sensory peripheral neuropathy, however, limits

Cisplatin to a dosage below the optimum (Legha & Dimery, 1985).
A preclinical model using the rat has shown a time and dose-dependent onset of
peripheral neuropathy by measuring the Hand M-reflexes (De Koning et al., 1987). Female 13
week old rats were treated with 1 mg/kg i.p. Cisplatin twice a week to a cumulative dosage of 19
mg/kg body weight. Furosemide (Lasix) was co-administered to prevent nephrotoxicity. After 47
days, corresponding to a cumulative Cisplatin dose of 13 mg/kg body weight, the SNCV began to
slow in the Cisplatin/saline controls. By day 67 (19 mg/kg body weight) SNCV had slowed to
76% of saline controls. No slowing of SNCV was observed in Cisplatin/Org2766 animals. No
change in MNCV was seen in either of the Cisplatin groups.
The De Koning et al. study also tested for interference of Org2766 with the anti-tumour
activity of Cisplatin. Female Lou/M Wsl inbred rats were injected with lgM-immunocytoma cells
on the left flank. Tumour growth was assessed twice weekly with vernier calipers and expressed
as the mean of three perpendicular measurements.

Cisplatin treatment began when tumour

mean diameter reached 1 to 1.5 cm. Animals were then divided into three groups: Cisplatin
plus saline; Cisplatin plus 1O µg Org2766 four times weekly; Cisplatin alone. No differences
were found between groups indicating Org2766 does not block the anti-tumour activity of
Cisplatin.
These findings were confirmed and extended demonstrating the neurotrophic actions of
Org2766 in the presence of Cisplatin.

In addition to preventing the neuropathy it was

demonstrated that Org2766 blocks further deterioration and accelerates recovery of an already
established Cisplatin-induced neuropathy in 12-13 week old rats (Van Der Hoop et al., 1988).
Administration of the peptide during an initial Cisplatin cycle results in improved resistance to
neurotoxicity during a second Cisplatin treatment cycle. The non-interference of Org2766 with
the anti-tumour properties of Cisplatin were again demonstrated in this study.
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In older rats, aged 7 mos, while Org2766 prevents onset of the peripheral neuropathy
when administered concomitantly with Cisplatin, no effects are observed when the peptide is
given to an animal with an existing neuropathy (Hamers et al., 1993a).

The authors speculate

that regenerative mechanisms are already maximally stimulated following 1O weeks of Cisplatin
treatment in the older animals.

However, others have shown that Org2766 can improve an

existing neuropathy in streptozocin-induced diabetic rats at 10, but not 1 µg/rat every 48 hrs
(Bravenboer et al., 1993).
Org2766 does not, however, influence the toxicity of Cisplatin in vitro on embryonic chick
brain cell cultures (Bruinink & Birchler, 1993). The same study did show that Org2766 increased
lysosomal activity, as assessed by neutral red uptake, and stimulated production of glialfibrillary-acidic-protein (GFAP).
Clinically, Org2766 has proven effective in preventing onset of peripheral sensory
neuropathy in women undergoing Cisplatin treatment for ovarian cancer (Van Der Hoop et al.,
1990). The analogue was administered s.c. (note the importance of route of administration as
discussed previously) at a dose of .25 mg (low dose) or 1 mg (high dose) per square meter of
body surface area immediately before Cisplatin administration and again 24 hrs later.

The

chemotherapeutic cycle was repeated every three weeks (with the same Org2766 regimen) for
six complete cycles.
The threshold of vibration perception, measured at the fingertips, was the main measure of
neurotoxicity. The threshold value for vibration perception increased more than two-fold after
four drug cycles in the placebo group. No change was observed in the high dose peptide group.
At the end of six cycles of chemotherapy, threshold values had increased by a factor of eight in
the placebo group, but only two-fold in the peptide group. Fewer neurologic signs were noted in
peptide vs. placebo conditions as well. Protective effects were noted, but less prominent, in the
low dose peptide group. No negative side effects were observed in either peptide condition.
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A continued deterioration in vibration

perception threshold values and

clinical

symptomology occurred in the patients described in the above study was observed after the last
chemotherapeutic cycle.

These changes were independent of treatment condition (peptide

administration ceased with the last Cisplatin cycle). After 4 months of worsening of symptoms a
gradual but incomplete recovery was observed at 12 and 24 months (Hovestadt et al., 1992).
The deterioration, however, was less severe in peptide patients. Such results indicate peptide
treatment should continue following cessation of Cisplatin administration.

The data further

suggest that Org2766 is effective in stimulating recovery long after the initial sprouting period.
Taxol has proven an effective anti-neoplastic agent of clinical importance (Rowinsky et
al., 1990) via its ability to greatly enhance the stability of microtubule polymers (Schiff et al.,
1979; Horwitz et al., 1986). The major current clinical indication of taxol is in treatment of
ovarian cancer refractory to Cisplatin (McGuire et al., 1989).

A largely peripheral sensory

neuropathy, similar to that of Cisplatin, limits dose and treatment length. Using the rat/SNCV
model, Org2766 completely blocks the deficit in SNCV observed in low (1.2 mg/kg 5 times
weekly for 7 weeks) and high dose (9 mg/kg once a week for 6 weeks) taxol administration
(Hamers et al., 1993b).
A double-blind, placebo-controlled trial showed that the peripheral neuropathy in patients
undergoing vinblastine-vincristine combination therapy for Hodgkin's and non-Hodgkin's
lymphoma could. be greatly ameliorated by concomitant treatment with 2 mg s.c. Org2766 on the
first and tenth day of a chemotherapeutic cycle (Van Kooten et al., 1992). Improvements were
noted in vibration and temperature sense, a reduction in autonomic complaints and fewer motor
and sensory disturbances following eight drug cycles.
Using electroreception in the catfish, lctalurus nebulosus, as a model for vincristineinduced peripheral neuropathy, it was shown that Org2766 administered 2 days, but not 1 day,
before local vincristine application, prevents the onset of the phase lag in electroreceptor organ
afferent activity (Neuman et al., 1993).
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Acrylamide, a synthetic resin, is a cumulative toxin that results in peripheral neuropathies
in both man and other animals by an, as yet, unknown mechanism (Spencer & Schaumburg,
1974). Similar to Cisplatin, the neuropathy is of the dying-back type with the sensory fibres
much more susceptible. Org2766 did not prevent the initial loss of motor coordination (due to
the loss of sensory feedback) as assayed by the landing foot spread and footprint length analysis
paradigms. The peptide did reverse the SNCV deficit when given concurrently with acrylamide ,
but had no effect when administration did not begin until after the last acrylamide dose. These
results suggest a need for early peptide treatment of chemically induced peripheral neuropathies.
While recovery of normal motor coordination, as measured, was unaffected by peptide, the
animals were more resistant to a second acrylamide challenge, possibly indicative of a more
complete recovery relative to saline controls.
In all, Org2766 has proven effective in preventing/ameliorating damage induced by
chemical challenge of more than one type.

Org2766 and CNS Injury

Septal lesions in the rat results in hyperemotionality as indexed by a large number of
behavioral parameters (Brady & Nauta, 1953) and facilitates acquisition and performance of
shuttlebox active avoidance behaviour (Poplawsky, 1978). The hyperemotionality decreases
progressively with time while the enhanced performance on the active avoidance task appears
permanent.
Adult female rats received bilateral electrolytic lesions of the septal area after having
been rated for emotionality on five rating scales: 1) reaction to object presentation; 2) response
to tap on back; 3) resistance to capture; 4) resistance to handling; 5) vocalization to capture and
handling (Isaacson, 1983). The peptide group received 1 µg Org2766 s.c. on the day of surgery
and post-surgical days 1, 2 and 3.

All animals were again rated for emotionality on days 3

through 12 in a blinded fashion. The two-way shuttlebox behavioral testing was conducted on
day 35.
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Mean emotionality was roughly half that of the saline control group in peptide treated
animals.

Both peptide and control rats made correct avoidance responses 82% of the time.

However, the Org2766 group made significantly fewer inter-trial crossings. Inter-trial crossings
are generally thought to reflect anxiety or some related hyperemotional state. Therefore, only
those behaviors which were of an emotional nature were affected.

The facilitation of the

avoidance response was unchanged by the peptide. This study did not differentiate between
whether the functional recovery was due to partial repair of the lesion area or to stimulation of
compensatory mechanisms, though it is likely the latter due to the relatively short duration of the
behavioral testing.
Adult male rats received bilateral electrolytic lesions of the parafascicular area of the
posteromedial thalamus (Nyakas et al., 1985).

Peptide groups were given s.c. injections of

either 10 or 50 µg of Org2766 every 48 hrs beginning on post-operative day 3 and ending on day
17. On days 7, 13 and 19 the lesion and sham-lesion groups were tested for open-field behavior
and T-maze reversal learning. In the open-field test 50 µg Org2766 decreased ambulation at
days 13 and 19 -relative to saline control in the sham-lesion group. No significant effects were
noted in the 10 µg group. For the T-maze reversal learning task rats were trained to go (either)
to the left or right arm of a T-maze on post-operative day 21. Animals with parafascicular lesions
make a greater number of errors during the (day 22) reversal phase.

Both 1O and 50 µg of

chronically administered Org2766 reverse this deficit with 50 µg returning error numbers to near
sham-lesion/saline levels. This reversal was not seen with a single (acute) peptide injection 1 hr
prior to testing.
Functional recovery from aspirative cortical, cortico-hippocampal or sham lesions was
followed in adult hooded rats (Hannigan & Isaacson, 1985). Animals were given either 1 µg s.c.
Org2766 or saline daily for one week post-surgery. Training and testing in a food search task
began on the day following the last peptide or saline injection. Rats with cortical lesions only, in
general, were profoundly impaired in food search performance and were not aided by peptide
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administration. Animals with cortical plus hippocampal damage were hyperactive, but learned
the task quickly. Note that behavioral impairments observed in rats with cortical lesions are not
seen in rats with both (overlying) cortical and hippocampal removal e.g. (Schmajuk et al., 1983).
The deficits in the hippocampectomized animals were of the type most commonly thought to
relate to attentional vs. memory processes.

Such attentional processes are thought to be

sensitive to emotive states.
Evidence has been reviewed above which is consistent with a role for Org2766 in
regulation of emotionality.

Org2766 dramatically improved performance using

measures in the study being discussed presently.

attentional

Sham-operated rats treated with peptide

showed a decrement in performance also indicative of impaired ability to attend to ongoing goaloriented type behaviors relative to saline animals (this is contrary to the human behavioral data
to be reviewed later). The authors conjecture emotional reactivity in the peptide-treated sham
animals was lowered below an optimal level. Similarly, reduced emotionality may have resulted
in improved performance on those tasks where high emotionality was thought to inhibit
performance. However, it is not possible, using the present literature, to differentiate between
effects of Org2766 on rat emotionality and possible effects on the reward value, if any, of the
food. It is clear that Org2766 attenuates error in goal-directed behavior of rats in a food search
task. The peptide can also result in a decrement in performance of control animals on those
types of behaviors postulated to be significantly influenced by affective state of the animal.
Org2766 can also stimulate recovery following damage to the vestibular system. Frogs
(Rana temporaria) underwent unilateral labyrinthectomy. Two groups of functional deficits are

generally noted with such lesions:

postural changes, such as curvature of the longitudinal body

axis, head deviation across the long axis and changes in extensor/flexor tone; secondly,
impaired dynamic vestibular reflexes. In general, the postural symptoms are greatly ameliorated
through compensatory mechanisms while the dynamic deficits do not recover as well (Precht &
Dieringer, 1985). Either .25 nM/kg/day or 1 nM/kg/day of Org2766 or saline was injected into the
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dorsal lymph sac each day for 24 days following unilateral labyrinthectomy. Half-compensation
times are operationally defined as the time over which the initial head deviation is reduced to
50% of that on the first day post-surgery. The half-compensation times serve as the dependent
variable.

Similar to the rat sciatic crush model, those frogs treated with either peptide dose

demonstrated a dramatic acceleration of recovery. The compensatory mechanism is not known
though the authors speculate a stimulation of collateral sprouts from remaining inputs in the
deafferented vestibular nuclei.
A series of experiments was performed to determine the effects of Org2766 on functional
and biochemical parameters following 6-hydroxydopamine (6-OHDA) lesions of the nucleus
accumbens, a key area of the ventral striatal motor system in mammals. Functional recovery
from lesion-induced motor hypoactivity is accelerated by daily s.c. or intra-accumbal injections
with 10 µg/kg or 10 ng per left and right nucleus accumbens, respectively (Wolterink et al.,
1990b). That is, the spontaneous recovery period of 3 weeks is shortened to 7 days by peptide
administration. Following behavioral testing, the in vitro levels of dopamine (DA), homovanillic
acid (HVA), a DA metabolite indicative of DA turnover, 3,4-dihydroxyphenylacetic acid (HVAC),
another DA metabolite, and [3H]-DA uptake were found to be reduced to 30-40% of control levels
in both control and peptide-treated animals (at least following 6 days of peptide treatment with
measurements performed on the seventh day). A Scatchard analysis of [3H]-haloperidol binding
of placebo or peptide treated animals on day 7 of sham operated animals suggested a single
type of DA binding site. A similar Scatchard plot was found with placebo-treated 6-OHDA lesion
animals.

A curvilinear Scatchard plot was found for 6-OHDA/Org2766 animals suggesting

induction of a second type of DA binding site by day 7.

An enhanced behavioral response

following apomorphine challenge in peptide-treated animals suggests induction of functional DA
(denervation) supersensitivity by Org2766.
Further experiments revealed intra-accumbal, s.c. and per os (p.o.) Org2766 routes of
administration were all effective as regards functional recovery from 6-OHDA lesions of the
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nucleus accumbens (Wolterink & Van Ree, 1990) at doses ranging from 0.01 to 100 ng/kg for
intra-accumbal injections, 0.01 to 10 µg/kg for s.c. administration and 1 to 10,000 µg/kg p.o. in a
dose-dependent fashion. It is not known why p.o. doses are effective in this model. The greatly
larger non-intra-accumbal doses needed to effect functional change indicate that Org2766 likely
exerts its effects locally on accumbens tissue. If peptide treatment is delayed until the fourth
post-operative day no beneficial effect is observed indicating the need for timely Org2766
administration in cases of CNS damage.

A single injection of biodegradable micro-spheres

releasing ~8-9 ng/kg/day Org2766 was also effective in acceleration of functional recovery from
6-OHDA lesions of the nucleus accumbens in rat (Wolterink et al., 1990a).
Org2766 is not effective in facilitating recovery from all types of CNS damage. Young
adult rats received aspirative lesions of the medial or lateral occipital cortex. Lateral lesions
have been found to have more severe functional consequences vs.
(Dean, 1990).

A third sham-lesion group served as the control.

medially placed lesions
Half of the animals were

administered 25 µg of Org2766 s.c. beginning on the day of surgery and continuing daily until
post-operative day 9 (Schmidt et al., 1992). All animals had been trained to criterion on a black
vs. white stimulus card used as an indicator of escape platform location in a Morris water maze.
Retention testing began 5 weeks post-operatively. A group was also included which was given
peptide during the retention testing only. Neither immediate post-surgical nor concurrent peptide
administration improved performance in this discrimination task. A group receiving peptide for
the full seven week period would have been desirable in this experiment.
The authors speculate the failure of Org2766 to promote functional recovery from medial
or lateral occipital lesions is because the nature of the impairment is neither memory nor
attentional, but may best be characterized as sensory/perceptual. Since control animals do not
recover from

occipital lesions this may be indicative that the peptide only affects recovery

processes that would have occurred in its absence.
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Org2766 Affects Learning/Memory in Intact Animals

Low dose (50, 100, 200 ng s.c.) and high dose (500, 1000 ng s.c.) Org2766 have
differential effects on a one-trial learning passive avoidance task whether administered pre- or
post-learning (Fekete & De Wied, 1982a). Irrespective of administration schedule, low doses
facilitated while high doses attenuated retention of a passive avoidance response. Both high and
lose doses of the peptide decelerated the rate of extinction of a pole-jumping active avoidance
behaviour in the same series of experiments.
As described in an earlier section, the differential effects on the passive avoidance task
can be attributed to different portions of the tri-substituted ACTH4-9 molecule. It is not known
why these differential effects are limited to the passive avoidance task though it is possibly due
to involvement of only partially overlapping brain areas between the two behaviors.
Spontaneous motor activity was measured in normal and cold-stressed 13 day old rats pretreated with 0.1 µg/kg/day Org2766 or saline from birth to the day before testing (Saint-C0me et
a/., 1982). Motor behaviour was quantified and categorized according to the following scheme:
horizontal movements consisting of head waving, forelimb and hindlimb movements, wriggling,
rolling, sniffing, pivoting, walking, running and grooming; ambulatory movements which were a
subset of horizontal movements including crawling, walking and running; the number of stop and
go movements. No peptide effects were found in non-stressed animals. When animals were
placed on a cold metal plate (0°C) centered in the activity chamber, both peptide and control
animals display an elevated level of motor activity after escaping the cold-stress.

However,

Org2766 pups maintained the high motor activity for the duration of the 5 min test period, while
controls were only highly active for the first 2 min.
Because Org2766 is known to accelerate development of neural circuitry, perhaps the
prolonged high activity under cold-stress is a function of this early maturation which becomes
evident under stress.

Depressed function and high metabolic rates such as that seen in

developing and regenerating systems are the prerequisites for neuropeptide effects on
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neuromuscular performance as reviewed in previous sections.

The authors

speculate that

stress is an additional state in which the effects of Org2766 become evident.
The tendency of ambulatory rat neonates to return to their mothers when separated was
used to study the influence of Org2766 on learning (Acker et al., 1985). The young animals were
treated with 0.01 µg/kg/day or 10 µg/kg/day s.c. Org2766 or saline from days 1 to 8.

The

injections were changed to an i.p. route from day 9 onward including the onset of the learning
acquisition phase. The learning task consisted of a T-maze with the mother placed in either the
left or right goal box. A successful response was tallied when the pup went first to the goal box
containing the mother. Pups treated with 0.01 µg/kg peptide, only, achieved the goal in half the
time vs. controls and made less than half as many errors in doing so. During the extinction
phase 24 hrs later low dose animals took significantly more trials to extinguish while maintaining
faster trial times with fewer errors (i.e. peptide pups went to the arm to which they were trained to
find their mother). Normal developing rats are known to run faster to the left than the right. This
differential is due to an asymmetry in dopaminergic nigrostriatal (Zimmerberg et al., 1974) and
cholinergic (Zimmerberg et al., 1974) function seen in developing animals.

Abolition of the

turning preference during the extinction phase in the .01 µg/kg group is interpreted by the
authors as an acceleration of maturation of the brain systems involved in the asymmetry.
Housing adult rats singly and/or under intense light levels markedly decreases motor
activity while group housing under low light conditions elevates motor activity. Subcutaneously
administered Org2766 (ED50 : 0.01-0.03 µg/kg) 50 min prior to testing normalizes motor activity
under both conditions (Wolterink & Van Ree, 1987). The normalization is blocked by systemic
naltrexone suggesting the direct or indirect involvement of opioid systems.

Perhaps these

effects on motor activity are indicative of the previously described effects of Org2766 on the
regulation of emotionality.
A followup by the same group showed that intra-amygdaloid injection of Org2766 produced
the same normalizing effect (Wolterink & Van Ree, 1989) which, again, is blocked by naltrexone.
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lntra-accumbal injections were not effective.

Antibodies to endorphins also blocked the

behavioral effects of Org2766, more directly indicating endogenous opioid systems are involved
in the normalizing effect.
An odor discrimination paradigm in the rat quantifies the difficulty the animals have in
rapidly reversing behavioral responses to previously learned odors.

The difficulty positively

correlates with an increase in the storage (depth) of olfactory information. Org2766 enhances
this storage when administered at either 5 or 1O µg/kg immediately before or after the learning
phase (Roman et al., 1989). Treated animals also demonstrated superior retention when retested 24 hrs after meeting acquisition criteria.
The learning/memory literature, in toto, is vast and will not be reviewed here.

While

various dichotomies have been used to classify learning/memory sub-types, one particular
scheme views learning/memory as either procedural (acquiring and performing skilled behaviors)
or declarative (storage and retrieval of single facts and associations) (Schacter, 1985).
Declarative learning/memory is thought to be probed in the odor discrimination paradigm.
Org2766 also has been tested for behavioral effects on humans in a non-clinical setting.
Adult male volunteers, in a double-blind placebo study, were administered 40 mg Org2766 p.o.
or placebo (Fehm-Wolfsdorf et al., 1981). In a two-stimulus reaction time paradigm the peptide
was found to facilitate attention directed to one set of stimuli, but impaired shifts of attention
between attentional sets.

Similarly, in a constant foreperiod reaction time paradigm 40 mg

Org2766 quickens reaction time (Rockstroh et al., 1981).
In a related double-blind study adult male volunteers received 40 mg Org2766 or placebo
in a paradigm designed to test for distractibility (Rockstroh et al., 1983).

This experimental

design is a modification of the constant foreperiod reaction time test. An acoustic stimulus S1
(pure sine tone of 1200 Hz, 65 dB) is presented for 6 sec and is immediately followed by tone S2
(600 Hz, 65 dB); which is to be interrupted by the subject as quickly as possible by pressing a
button. Having reached criterion performance level the test is repeated, but with 50% of the
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trials a distracting background pulse is pseudo-randomly interspersed during the entire S1-S2
interval. All experimental sessions were scheduled at 1430 and 1630 hrs when endogenous
ACTH secretion is low. No statistically significant differences were found between groups, but
response latencies of the peptide subjects, with and without distraction,

were ~10% longer

suggesting an impairment of switching between attentional sets.
Org2766 and Aging

The rat hippocampus, which is rich in corticosterone receptors, undergoes reduced
morphological correlates of aging following long-term adrenalectomy.

Adrenalectomized

animals not only have greatly reduced circulating levels of steroid hormones, but also display
elevated serum concentrations of ACTH. Perhaps the elevated ACTH levels are responsible for
the retardant effects of adrenalectomy on aging morphological correlates rather than reduced
circulating steroids. To address this question, middle-aged rats were either adrenalectomized
and chronically maintained with corticosteroids or left intact and chronically treated with s.c.
Org2766 for 9 to 10 mos (Landfield et al., 1981).

Both the peptide group and the animals

maintained on steroids showed increased neuronal density, nuclear roundness, decreased gliosis
and a lowered brain aging index, which is a composite of the listed variables, relative to aged
controls. Of interest, several adrenalectomized animals exhibited markedly fewer brain aging
signs vs. peptide animals suggesting steroids may interfere with peptide effects.
Aged rats demonstrate an attenuated glucocorticoid feedback response which results in
chronically elevated circulating steroids (Sapolsky et al., 1984).

The Type-I corticosterone-

preferring receptor, located in highest densities in hippocampal and septal areas (Reul & de
Kloet, 1985), is involved in the coordination and synchronization of such daily activities as
exploration, food-seeking and sleep-related events (Bohus et al., 1982).

The Type-II

glucocorticoid receptor regulates glucocorticoid feedback repression of corticotropin-releasingfactor (CRF) and POMC pituitary release (Dallman et al., 1987).
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To assess the effects of Org2766 on Type-I and Type-II glucocorticoid receptors, three and
thirty month old rats were treated for two weeks with Org2766 via a 10 µg s.c. injection on day 1
and a s.c. implanted mini-pump releasing 0.5 µg/hr or saline control for 13 days (Reul et al.,
1988).

All animals were adrenalectomized on day 13 to deplete the receptors of endogenous

corticosterone and were sacrificed 24 hrs later. In the aged control group, a 52 and 28% decline
in Type-I and Type-II receptors, respectively, was noted in both hippocampus and septal areas.
Org2766 induced a modest 8% increase in Type-I receptors in young rats, but a 68% increase in
old rats. No changes were observed in Type-II receptors in young or aged animals. Neither
were any alterations in

~

seen for Type-I or Type-II receptors for corticosterone.

The effects of chronically administered Org2766 were investigated as regards the agerelated degeneration of serotonergic fibres and on gliosis in the rat hippocampus and caudateputamen. Eleven month old rats were s.c. injected with either 1 or 100 µg/kg Org2766 three
times a week for 6-7 mos (Van Luijtelaar et al., 1992).

The peptide had no effect on the

incidence of age-related degeneration of serotonergic fibres in the hippocampus or caudateputamen. Neither did Org2766 demonstrate neurotrophic properties when administered to young
rats with hippocampal lesions implanted with fetal serotonergic cells. Staining for glial fibrillary
acidic protein (GFAP) revealed no changes in gliosis in peptide vs. control.
Clinical Effects of Org2766

Patients with Senile Dementia Alzheimer's' Type (SDAT) as defined by the Diagnostic and
Statistical Manual Ill (DSM Ill) were studied in a double-blind, placebo-controlled study (KraghSorensen et al., 1986).
conditions.

Subjects were excluded with confounding medical or psychiatric

Those patients on psychoactive medication were also excluded.

Only those

individuals with mild to moderate dementia were used. Subjects received placebo, 5, 20, 40 or
80 mg Org2766 p.o. per day for 28 days. Org2766 was found to have a small but significant
therapeutic effect as assessed by the Sandoz Clinical Assessment Geriatric Scale. However,
only 25% of the subjects displayed improvement and no dose-response relation was observed.
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These results suggest the need for studies of a much longer time-course.

The degenerative

processes resulting in the clinical dementia likely develop over many years and it is not
reasonable to expect a neurotrophic agent to show maximal effects, if any, following a 28 day
treatment period.
A recent study looked at larger doses (40, 60 and 80 mg/BID p.o. for 12 weeks) of
Org2766 in a double-blind study similar to the study outlined above (Miller et a/., 1993). Highdose peptide resulted in significantly faster reaction times on behavioral tasks and a clinically
defined improvement in alertness relative to control.

No effects were seen on the Global

Deterioration Scale designed to assess overall cognitive and affective function.

This study

shows that high oral doses of Org2766 are well tolerated, but longer treatment periods may yet
be indicated.
In a double-blind, placebo controlled study, patients diagnosed with either panic disorder,
generalized anxiety disorder or social phobia were treated for six weeks with 80 mg Org2766 p.o.
(Den Boer et a/., 1992). A small reduction on the Hamilton Anxiety Scale was observed in the
panic disorder group with no change in the number of attacks (as in the den Boer (1989) study).
No anxiolytic effects were seen in the generalized anxiety or social phobia subjects.
Adult male and female subjects diagnosed with panic disorder (DSM 111-R)

with and

without agoraphobia were treated with 40 mg/BID Org2766 in a double-blind, placebo controlled
study (Den Boer et a/., 1989). While the peptide had no effect on the number of panic attacks, it
did lessen the anxiety associated with the disorder much as in the previous study.
Autism is a child-onset persistent psychiatric disorder characterized by deficits in social
interaction including stereotyped behaviour patterns, abnormal cognitive, language and
communicative function (Cohen & Donnellan, 1987). Daily treatment with 40 mg/day Org2766
p.o. in a double-blind, placebo-controlled, cross-over study resulted in improved eye contact,
disconnection of verbal initiative (e.g. putting a question or changing a topic of conversation)
from stereotypes (e.g. repetitive asking of a question) and connection of verbal initiative to non-
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verbal gestures (e.g. pointing or showing).

Additionally,

psychiatrists and psychologists not

associated with the experiment noted substantial improvement on clinical scales.

Parents

reported a decrease in social withdrawal behaviors at home. A second controlled cross-over trial
resulted in lessened social withdrawal and improved play behaviour (Buitelaar et al., 1992).

Org2766: Mechanistic Studies

A seminal study investigated the effects of substitutions in the ACTH4-9 molecule on the
extinction of an active avoidance behaviour in intact rats (Witter et al., 1975). The previously
described introduction of 4-Met-sulfoxide, 8-D-Lys and 9-Phe resulted in a 1000-fold increase in
behavioral potency with a concomitant 1000-fold decline in melanotropic activity. Since there
exists a strong positive correlation between behavioral activity and the in vitro half-life of
substituted ACTH4-g it is believed that resistance to bio-transformation explains, in part, the
increased potency of the analogue.
Uptake of [3H)-Org2766 into specific brain regions of the rat were studied via i.c.v.
injections of the labeled peptide (Verhoef et al., 1977).

lntra-cistemal (cisterna magna)

or

peripheral administration of the peptide resulted in inadequate brain labeling likely due to CSF
flow dynamics ~nd degradation, respectively.

All major brain regions were then assayed for

peptide using quantitative autoradiography.

Highest uptake occurred in the septal area,

thalamus and hypothalamus with equal labeling observed in most other brain regions including
hippocampus and basal ganglia. The lack of high uptake in hippocampus and basal ganglia is
somewhat surprising given the involvement of these areas in peptide effects in previously
reviewed studies. The answer may, in part, be that high uptake may not necessarily correlate
strongly with functional effects. Although there is a positive correlation between peptide uptake
and distance from the ventricular system, this does not explain all of the variance as other major
unlabeled structures reside adjacent to the ventricles, yet do not label heavily (e.g. caudateputamen).

[3H]-Phe was used as a control and showed more even labeling vs. Org2766. This

suggests that the uptake and/or binding sites for labeled Org2766 are distinct from those which
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result in labeling with the single residue. This study is suggestive only as preferential uptake
does not necessarily indicate site(s) of action. Uneven labeling may largely be due to differences
in accessibility and uptake capacity for the peptide. Likely the most important factor in peptide
activity is its availability in optimal amounts

at appropriate sites.

Other labeling may be

irrelevant or antagonistic as regards a specific effect.
Related to the above study, local cerebral glucose utilization was studied in rat brain
following 100 µg/kg/day i.p. Org2766 using an autoradiographic 2-deoxyglucose (2-DG)
technique (McCulloch et al., 1982). Significant increases in glucose utilization measured as 2DG uptake were observed only in the hippocampus (stratum moleculare lacunosum and
parasubiculum show increases in 2-DG uptake of 16 and 17%, respectively), anterior nucleus of
the thalamus (23%) and anterior cingulate cortex (30%) of the 49 anatomically distinct brain
areas studied. Note that no changes were observed in the septal area, though a non-significant
13% increase was observed in the lateral septal nuclei.
Interestingly, all of the areas showing elevated glucose utilization are classically defined as
belonging to the limbic system (a system important in learning/memory, emotive, motivational
phenomena). No effects were seen in basal ganglia (motor integrative/output system) or cortical
areas involved in visual, auditory or somatosensory processing.

This study provides no

definitive information as to the primary site(s) of action of Org2766, but is merely suggestive of
the functional involvement of these areas in peptide effects.
Of importance, the parasubiculum is the origin of major hippocampal projections to the
anterior thalamic nucleus (Carpenter, 1976) while anterior cingulate cortex and anterior thalamic
nucleus have extensive reciprocal projections (Domesick, 1969). This hippocampal, thalamic,
cingulate circuit could provide the anatomical basis for the motivational hypothesis of ACTH
analogue action as proffered by De Wied (De Kloet & De Wied, 1980).

In support of this,

cingulate cortex interactions with the anteroventral thalamus have been shown to be important in
learning and behaviour (Gabriel et al., 1980).
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The 150 kDa neurofilament subunit has been shown to contain an immunologically
recognized a-MSH segment (Drager et al., 1983). This is the same protein that has been shown
to break down in the early stages of peripheral nerve degeneration (Bignami et al., 1981) coinciding with the onset of neurite regrowth. Degenerating peripheral nerve contains a factor that
is active in a MSH bioassay (Edwards et al., 1984) that is not expressed in control nerve. This,
as yet, unidentified protein with a-MSH-like growth promoting activity may be a breakdown
product of the 150 kDa

neurofilament subunit.

It is conceivable that Org2766 mimics this

endogenous protein since both a-MSH and Org2766 share a common, but modified, primary
sequence.
The in vitro binding of [3HJ-Org2766 to rat spinal cord sections as assessed via quantitative
autoradiography reveals an uneven binding distribution across spinal cord structures which is
only partially displaceable by cold peptide (Dekker & Tonnaer, 1989)

possibly indicating the

involvment of a non-classical binding site or, alternatively, non-specific binding. Labeled peptide
was not naloxone-displaceable making the binding site distinct from the opiate receptor. A leftright difference was observed in spinal cord dorsal horn binding 6 days following unilateral sciatic
crush at level L2, but not T10. Only the L2 binding sites were displaced by cold peptide with
neither L2 nor T10 peptide binding being naloxone displaceable. This differential disappeared at
28 days corresponding with return of sensorimotor function. The relation, if any, between CNS
Org2766 binding and regeneration of crushed sciatic nerve is not made clear by this experiment.
Perhaps the peptide is binding afferent neurites or glia in the dorsal horn.
A partial answer is provided by a study measuring the biotinylated-Org2766 (b-Org2766)
binding to in vitro dorsal root ganglion (DRG) and spinal cord (SC) cultures (Van Huizen et al.,
1991). Displaceable b-Org2766 binding occurred on neurofilament containing cells with round
somata and fine.processes in both culture types. In comparison with nerve growth factor (NGF),
Org2766 had little effect on neurite outgrowth in DRG cultures. The authors did report, in the
same abstract, preliminary evidence that neurite branching may be altered by Org2766.
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Delayed neuronal death of non-dissociated DRG and SC cultures obtained from embryonic
(day 15) rats is reported in the presence of Org2766 (Lee et al., 1991). The same abstract
reports preliminary evidence that Org2766 may stimulate neurite outgrowth in these cultures,
contrary to the findings of Van Huizen and co-workers.
In contrast, others have shown that a.-MSH and ACTH 1_24 stimulate synthesis of GAP-43
and neurofilament dose-dependently at 48 and 96, but not 24 hrs in dissociated fetal rat spinal
cord neurons (Van Der Neut et al., 1992); whereas, Org2766 had no effect on these parameters.
In DRG cells in vitro in the same study, a.-MSH increased neurofilament levels by 22% and GAP43 by 54% with an inverted-U shaped dose-response curve.

Neither ACTH4- 10 nor Org2766

were effective in changing GAP-43 or neurofilament levels in either of these preparations.
Alpha-MSH, but not Org2766, induces expression of c-fos, one of the immediate early gene
proteins implicated in a variety of processes related to cell change, in dissociated rat spinal cord
neurons at dose ranging from 10-13 to 10-4 M (Hol et al., 1993a).

The authors chose this

particular culture system because, of the two peptides, only a.-MSH has a trophic effect on these
neurons. This is suggestive that c-fos may be involved in the mediation of the neurotrophic
effect of a.-MSH.

Further studies are needed to ascertain whether those in vitro systems

responsive to Org2766 also show an increase in c-fos mRNA. This result is of particular interest,
as the same group showed in a later study that both a.-MSH and Org2766 induce an increase in
cAMP-activity in dissociated rat spinal cord neurons (Hol et al., 1993b).
Large axons of the cerebral commissure of Lymnaea Stagnalis are stimulated to produce a
30% increase in the number of microtubules in vitro in the presence of 1o-8 M Org2766 (Muller et
al., 1992), with 10-s M producing a maximal effect. Log doses one to three magnitudes greater
produced no further increase in the number of microtubules. A dose of 1o-9 M had no effect on
microtubule number. This experiment does not reveal whether the mechanism for the effect
involves tubulin synthesis, increased microtubule assembly or a stabilization of existing
microtubules. However, ultrastructural data shows alterations in glial cell morphology such as an
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increase in the number of filament bundles, the presence of irregular circular structures
resembling smooth endoplasmic reticulum and less pronounced chromatin condensation along
the nuclear envelop suggesting a more general effect of Org2766 on CNS tissue.
Org2766 showed no effect on nerve cell differentiation as indiced by changes in
microtubule-associated-protein-5 (MAP-5) and the 68 kD neurofilament (NF 68 kD) subunit in
embryonic chick brain cell cultures (Bruinink & Birchler, 1993) indicating that these growthassociated proteins are not affected. This study, however, used 400 µM Org2766; lower doses
were not tested. The inability of Org2766 to lessen Cisplatin toxicity in the same in vitro study
may indicate that compounds working directly at the DNA level are more resistant to the
protective effects of Org2766, though others have shown that the peptide does ameliorate
Cisplatin neurotoxicity in an in vivo rat model (De Koning et al., 1987). The Bruinink study did,
however, show significant delayed toxicity of Cisplatin on the culture even 192 hrs after Cisplatin
wash-out.

A significant increase in GFAP, but not MAP-2 was noted at 10° and 10-1 M, but not

at lower doses. These results indicate the importance of dose-response testing when conducting
studies using Org2766.
Fast anterograde axonal transport rates in normal rat sciatic nerve is not altered by 7 day
treatment with either 1 or 1O µg/kg/day i.p. Org2766 (Crescitelli et al., 1989) following injection of
[ 3H]-Leu

into lumbar spinal cord. Crest height, indicative of the quantity of transported labeled

protein, was decreased 62 and 64%, respectively, at 1 and 10 µg/kg/day.

Damaged nerve,

unfortunately, was not used with Org2766 in this study. ACTH4- 10, however, changes neither
rate nor crest height in regenerating sciatic nerve. The crest height is doubled by ACTH4-10 in
undamaged nerve, though a large variance prevents statistical significance.
Rats receiving intra-accumbal injection of control serum during the first week following 6OHDA lesions display similar levels of motor activity at 3 weeks post-lesion as sham-lesion with
control serum (Wolterink et al., 1990c). Rats with similar lesions treated with antisera to a-MSH
or Org2766 fail to recover at 3 weeks. The antisera had no effect on sham-lesioned animals.
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Apomorphine challenge in recovering lesion animals treated with control serum results in
increased motor activity, but not in animals administered antisera. This result and the absence
of elevated [3H]-haloperidol binding in nucleus accumbens of antisera treated animals is
indicative of the lack of development of denervation supersensitivity.

This evidence is

suggestive that Org2766 and other MSH-like analogues may mimic endogenous peptides which
mediate CNS recovery processes.
Though GAP-43 is generally thought to be a neuron-specific protein, the mRNA has been
found in the sciatic nerve of control rats (Plantinga et al., 1993, 1992) indicating localization in
Schwann cells.

The message is up-regulated in DRG 18-fold following crush injury.

Surprisingly, mRNA message increases dramatically in the distal nerve stump 2 days following
crush or transection, remaining elevated for the period corresponding with return to complete
sensorimotor function. No changes in message are observed in the proximal portion of injured
nerve. In situ hybridization showed heavy staining for GAP-43 mRNA adjacent to Schwann cell
nuclei. These results were confirmed by Northern blot analysis.
Transcription of GAP-43 message appears, therefore, to be regulated by Schwann cell
interactions with nerve cell axons. Given the previously reviewed evidence for regulation of
protein synthesis by ACTH and derivatives, perhaps Org2766 stimulates GAP-43 expression in
DRG and in Schwann cells distal to the lesion site as a (partial) mechanism of action in recovery
from peripheral nerve mechanical damage.

Of interest, there is evidence of developmental

regulation of GAP-43 in rat neonatal cortex. GAP-43 also remains at detectable levels in adult
rat cortex and co-migrates with B-50, a synaptic membrane protein which is a preferred substrate
of protein kinase C in adult brain (Jacobson et al., 1986). In line with the action of Org2766 at
the lesion site it_ has been shown that transected rat sciatic nerve wrapped in Accurel™ tubing
impregnated with a-MSH (tubing restricts peptide to lesion site) accelerates functional recovery
(Edwards et al., 1986).
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Conclusions

Evidence has been reviewed here implicating Org2766 in a variety of developmental,
regenerative, behavioral, aging and degenerative phenomena. The mechanisms by which these
effects are produced largely remain to be elucidated. The experiments described in this work
test for neurotrophic effects of Org2766 on a nerve cell-like immortalized cell line. These in
vitro studies have the advantage of controlling for effects on glial cells and/or other systemic

actions of the peptide. Disadvantages include the limited generality of any findings as these are
transformed cells operating in the absence of the native systemic environment.
Measurement of Finite Closed Curves

Introduction

For the purposes of the present work a finite closed curve may be conceptualized as a line
segment of determinable length having the same start and end-points with the further stipulation
that it be non-intersecting, though these criteria obviously do not necessarily hold for all closed
curves. The curves considered here are embedded in two-dimensional Euclidean space; hence,
each point of the curve can be referenced by two descriptors such as two real numbers
corresponding with

positions on the x and y-co-ordinate axes of a Cartesian plane.

The

intersection of the perpendiculars to the axes for each co-ordinate x-y pair maps the positions of
the points in two-space.
The closed curves of interest here define the 2-D contour of well-differentiated nerve celllike tumor cells grown in culture at the peripheral attachment points of the cell to the culture dish.
The problem arises as how to quantifiably define these shapes as well as the first time derivative
of the shape. Traditional approaches within the cell morphometry literature are discussed in light
of their relative advantages and disadvantages.
Morphometric Approach

A common approach to quantifying changes in cell morphology is to measure cell area or
the change in area over time e.g. (Davies & Cox, 1991). Others have measured neurite length
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or change in length as a function of time e.g. (Gupta et al., 1987). The enumeration of cell
structures of a particular type such as veil, filopodia e.g. (Burmeister & Goldberg, 1988) or
growth cone configuration (Aletta & Greene, 1988) has also been done , as well as the mere
listing of the presence or absence of structures of a type e.g. (Yong et al., 1988; Van Der Neut et
al., 1988). The dynamic extension/retraction of filopodia (Sheetz et al., 1992) and single axons

(Jhaveri et al., 1991) has also been studied.

In addition, various morphological qualifying

schemes have been employed such as defining a given morphology as to roundness, thinness
and branchedness (Luckenbill-Edds & Kleinman, 1988).
Each of the above methods has demonstrated a degree of utility correspondent with
individual applications.

The size measurements such as area and length, however, fail to

encode any shape information.

The qualifiers (e.g. branchedness), while providing some

intuitive indice relating to shape fall short of specifying shape information in terms that are useful
in making comparisons within or between groups of contours.
The form factor (FF) has also been used to quantify the relative complexity of a closed
contour. This measure is operationally defined as:

FF = 41rArea I Perimeter 2

(2.1)

For a circle of any radius, FF is equal to 1. As a shape tends towards the infinitely complex, FF
approaches zero in the limit.

However,

while FF does provide information as to relative

complexity, it suffers for its lack of ability to provide a unique measure. That is, there are an
infinite number of shapes with identical form factors.

The form factor is, in fact,

merely a

reformulation of size data (area and perimeter); hence, contains no shape information.
The landmark approach to morphological characterization has been well developed
(Bookstein, 1991). Landmarks are reproducibly recognizable features of a contour or surface.
The shape or changes in shape can then be quantified by changes in location of general and
specific features or points in relation to the landmark points. This method is of little use in the
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description of the closed curves of concern here as candidate landmark features tend to be
transient if existent.
Fractal Geometric Approach

The geometry of Euclid serves well in describing and defining many curvilinear structures,
especially those forms and surfaces associated with architecture and engineering.

The

Euclidean framework, however, is often inefficient or ineffective in describing natural entities
such as PNS or vascular geometry in the spatial domain or the probabilistic opening/closing of
an ion channel in the temporal domain.
When studying the spatial or temporal characteristics of these phenomena a repetitiveness
in form and spacing, respectively, can be observed that is resolution independent (Barnsley et
al., 1986).

A geometry has been developed to describe and analyze such fragmented non-

Euclidean structures. This mathematical framework is commonly referred to as fractal geometry
(Tsonis & Tsonis, 1987).
A brief discussion of dimension (D) is necessary in order to explain the concept of a fractal
and the accompanying fractal dimension (Dt>·

In general, there are two basic definitions of

dimension: Euclidean dimension (DE) and topological dimension (Dr), both of which can assume
only integer values. For a given object DE and Dr cannot be identical. Cuts, called surfaces, are
made in order to divide space into local domains. In the same sense, curvilinears can be used to
divide surfaces. A point, not being a continua, cannot be further divided.
Topology, the study of surfaces (Barr, 1964), tells us that since curvilinears can be divided
by point-like objects which are not continua (Dr = 0), the curvilinear is a continua of dimension
one (Dr= 1). A surface is a continua of dimension two (Dr= 2) since it can be divided by a
curvilinear. Everyday (non-relativistic) space is a continua of dimension three (Dr = 3) since it
can be partitioned by a planar surface of dimension two. In an intuitive sense, Dr reveals the
number of parameters necessary to describe any point on the surface once on the surface.
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DE is a measure of the minimum number of parameters needed to map the points of an
object in entirety. A curved line in two-space, which has a Dr equal to one, has DE equal to two
since both an x and a y value must be given to describe each point. Similarly, a curved planar
surface in three-space requires x, y and z co-ordinates for its full description (DE = 3). Only two
values are needed to describe each point once on the surface (Dr = 2). As is clear, in general

Dr = DE - 1 with exceptions such as the case of a straight line embedded in one-space where Dr

= DE or the case of a curved line embedded in three-space or any higher dimensional space.
Again, intuitively, DE is an index of the number of parameters needed to describe each point on
the surface without already being on the surface.
Consider the case of a curved line embedded in two-space (Dr = 1; DE = 2).
object 1

$

For this

D, $ 2; i.e. D, can assume non-integer values. In a physical sense the curve under

consideration has a dimension residing between that of a line and a surface so that, in a sense,
the line approaches having an area.

For a planar surface where 2

approaches attainment of a non-zero volume metric.

$

D,

$

3, the surface

With the above as background the

discussion proceeds to the concept of fractal.
The following is a modified recapitulation of the classic example of a fractal as related by
Mandelbrot (Mandelbrot, 1983). Assume measurement of a straight line segment using a rigid
index of length s. The total length is measured by walking along the segment in steps of length s
with each new length beginning where the previous step left off. If the number of steps is N(s},
then s

x

N(s) gives the total length L(s). If the procedure is repeated as s becomes vanishingly

small, N(s) tends toward infinity in the limit of small s, but L(s) remains constant. If the logarithm
of N(s) is then plotted as a function of the logarithm of s, the function describes a straight line
with negative slope, S. So, it follows:

N(e) oc e0

(2.2)

L(e) oc e1+0

(2.3)

and;
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By letting o=S = -D;

(2.4)
and;

L( c:) OC c:1- 0

(2.5)

The quantity D is variously referred to as the similarity or Hausdorff-Besicovitch dimension
(Mandelbrot, 1983). In the case of a straight line, D = 1, which also is the value of DT for a
straight line.
In the event of repeating the described procedure using a curve which cannot be described
by Euclidean geometry, such as a coastline, L(e) tends to infinity in the limit of vanishing e. The
reason for this outcome is that greater detail of the coastline becomes evident with shrinking
measuring step, e. In the case of the coastline, relations (2.4) and (2.5) hold, but D can now
assume non-integer values; therefore, D can now be fractional (i.e. fractal dimension terminology
arises from this fact).

From this Mandelbrot offered the following definition of a fractal

(Mandelbrot, 1983): "A fractal is a set for which the Hausdorff-Besicovitch dimension (Dt, fractal
dimension) strictly exceeds the topological dimension (~)-" As mentioned previously, Df must
also be less than or equal to DE.
The fractal geometric approach has been successful in such applications as predicting the
location of an enzymes active site as a function of the value of Dt (Lewis & Rees, 1985) and
revealing correlations between the physical behaviour of pharmaceutical

granules and their

topology (Thibert et al., 1988). Further applicationss include the use of fractal geometry in the
study of the effects of surface morphology on drug dissolution (Farin & Avnir, 1992) and the
modeling of discharge patterns following dielectric breakdown (Niemeyer et al., 1984).
The major shortcoming in using a Dt value as an indice of shape is the same as that of the
form factor (FF); that is, Dt is not a unique descriptor. This non-uniqueness means that a given
closed curve can, in principle and fact, change shape with no concomitant change in Dt. If there
is a change in Dt following alterations in the contour, Dt does not provide a meaningful indication
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of the magnitude of change. It is also important to realize that the scaling Df detects occurs only
over a limited range in the biological structures of interest in this work. Contributions to L(E) by
molecular and sub-molecular structures are beyond the resolution of the optical and digital
devices used.
Delta analysis is a related method well-suited to the characterization of fine structure or
surface roughness (Clark & Meloy, 1985). The delta analysis measures the angular change
between two vectors which are stepped around the contour.

Smooth surfaces generate low

values for the delta value while larger angles are indicative of a curve with a highly irregular
shape at small scales.

This is the most useful approach reviewed to this point as regards

providing true shape information. Similar to FF and Df, however, delta analysis is a non-unique
measure and is not necessarily sensitive to changes in shape.
A Fourier Analytic Approach

In light of the above discussion, it becomes apparent that what is needed is an analytic
method which not only embodies shape information, but is also sensitive to all size changes in
shape in a reliable, reproducible and quantifiable manner.

Additional requirements include

insensitivity to size scale (dilation), relative rotation of the contour in the plane of study and
relative position (translation) of the contour within the plane. Such methods are now used in
applications to analyze cell and nuclear contours for automated cell-recognition routines e.g.
(Diaz et al., 1989; Kuhl & Giardina, 1982; Diaz et al., 1990; Holmquist et al., 1978) and
recognition of surface features in quality control routines where a fluid energy mill is used to
break solid particles to minimal size in order to maximize surface area for optimal solubilization
and bioavailability (Akbarieh & Tawashi, 1987). Each of these methods is derived from the basic
technique Fourier used to describe the conduction of heat within an iron ring (Fourier, 1822).
A brief discussion of the application of Fouriers' method (by Fourier) to describe the heat
distribution as a function of time of an iron ring will be helpful in gaining an intuitive
understanding of the method.

This intuitive explanation adapted from Bracewell (Bracewell,
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1989) will be followed by a more formal treatment, also as recounted by Bracewell (Bracewell,
1990).
An iron ring is placed part way into a fire until a portion of the circumference is red hot.
The ring is then withdrawn and buried in a fine insulating sand and the temperature is recorded
at multiple points around the circumference as a function of time. The initial heat distribution is
irregular, with part of the ring uniformly hot and part uniformly cool with abrupt shifts in
temperature in between. As time progresses the temperature around the ring can be described
by a sin function with a uniform increase and decrease in temperature around the circumference.
The sinusoidal temperature distribution slowly flattens until the ring is of uniform temperature.
Fouriers' idea was that the initial irregular temperature distribution could be decomposed
into a number of sin functions, each with its own amplitude, frequency (of some integer value)
and phase (corresponding with position on the circumference).

The single-cycle variation is

known as the fundamental or first harmonic while the second, third, fourth,
second, third, fourth,

etc. cycles are the

etc. harmonics. The Fourier transform is the mathematical function that

gives the maximum temperature (amplitude) and position (phase) for each harmonic. The initial
heat distribution which is difficult to describe mathematically has been reduced to a more
manageable series of sin and cos functions that could be summed (or integrated in some cases)
to produce the original heat distribution function.
The Fourier analysis, in the example given, takes an amplitude existing in the spatial
domain and transforms it into an amplitude and phase residing in the frequency domain. It is
important to note that for a given function if a sufficient number of harmonics is included in the
analysis the original function can be described to any desired degree of accuracy .
A more formal presentation of the transform concept follows. Start with some function,
such as:

f(x) = exp(-lxl)

(2.6)
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The discrete Fourier transform of f(x) consists of multiplying the original function, in this case
(2.6), by:

exp{-i2m,x)
where u is the transform variable and i = ~ . Now,

(2.7)

having multiplied (2.6) by (2.7) the

resultant function F(u) is said to be the Fourier transform of f(x). The result of this operation is:

F( v) = 21[1 +{2n-v)2]

(2.8)

Note that for any given value of F(u), such as F(3) = 0.00561, the result 0.00561 depends on the
entire range of x, not on any single value of the original function.

This dependency is quite

different from what happens when an operation converts (2.6) to:

F(x) = sin[ exp(-lxl)]

(2.9)

The result (2.9) is referred to as a "function of a function" and each output value of (2.9) depends
only on the input value, not on the shape of f(x) as a whole.
The Discrete Fourier transform of f('t) is given by:

1 N-1
F( v) = f( i-) exp( -i21rvr/ N)
N

L

(2.10)

t=O

Consider the case of the Fourier transform of a space-varying signal, such as the closed
finite curves of interest to the present work: A curve can be represented parametrically as a
function of arc length by the cumulative vector tangent angle to the curve at each point since the
(arbitrary) starting point (Zahn & Roskies, 1972).

Call this net tangent angle, ~. and the

associated length function, ~(Q. The net tangent angle, ~(Q, in a sense, takes the place of the
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time-varying amplitude function discussed earlier; therefore, cj>(/) becomes the independent
variable and the analysis proceeds, in general, as follows:
The spatial function, cj>(/), can be expanded in a Fourier series:

(2.11)

Where:

(2.12)

(2.13)

The Fourier coefficients An and Bn index the contribution of the sin and cos functions at each
harmonic. The harmonic magnitude, Mn, is then defined as:

(2.14)

The detection of changes in shape, in the present work, is made via comparison of the
Mn's at each harmonic (n) as the contour changes over time. Intuitively, the value of M1 is an
indication of the circular contribution to the contour shape (any finite closed contour is going to
have a very significant value at M1 due to the 2n periodicity).

Similarly, M2 quantifies the

elliptical contribution, M3 , the triangular component, etc. The finest shape features are contained
in the higher frequency terms (Bookstein et al., 1982).
The strength of this method lies in the fact that the Fourier transform of the cj>(/) function
retains shape information, is sensitive to small changes in shape if a sufficient number of
harmonics are computed and is invariant to dilation, rotation, translation and reflection.

CHAPTER Ill
MATERIALS & METHODS

Cell Culture

The cells used in all

experiments described here were murine neuroblastoma cells,

designated Neuro-2a. These cells, obtained from American Type Culture Collection (ATCC;
Rockville, MD),· were first isolated from a spontaneous mouse CNS tumor in 1940 and
maintained via serial transplantation until 1969 (Van Kooten et al., 1992), at which time they
were sub-cloned to produce the present strain. The cell-line was received from ATCC following
Passage #172. The Neuro-2a line exhibits a variety of morphologies with most being neuronlike and well-differentiated. These cells express microtubular protein in high concentration as
well as levels of tyrosine hydroxylase similar to that seen in midbrain structures.
The line was further sub-cloned for the morphological study (Experiment 3) to yield a cellline with maximum arborization. The sub-clone is designated Neuro-2a-C8 in the present work.
No more than 20 passages were performed during any experiment before fresh cells were
retrieved from liquid nitrogen storage. Stock cells were grown in 25 cm 2 Falcon tissue culture
flasks at 37 °C in a humidified, 10% CO2 / balance air atmosphere. Culture media consisted of
Eagle Minimum Essential Medium (MEM; Sigma) with non-essential amino acids, Earle's
Balanced Salt Solution (EBSS) with L-glutamine (L-Gln).

Sodium bicarbonate (NaHCOJ> is

added to adjust media pH to 7.4.

The MEM, purchased as a powder, was solubilized with

double-distilled, de-ionized water.

The media solution was then filter-sterilized to ensure

freedom from contamination. Penicillin (100 IU/ml) and streptomycin (100 µg/ml) (PIS) were
added to decrease the probability of bacterial infection.
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MEM is designed to closely approximate the protein composition of cultured mammalian

cells.

The MEM was supplemented with 10% fetal bovine serum (FBS; Gibco BRL) for the

growing of stock cells.
minimize variability.
indicated.

The FBS used in all experiments was from the same lot number to

FBS concentration was reduced to 0.5% for individual experiments, as

The 0.5% FBS concentration was empirically determined to maximize cell

differentiation.
As cells grew to confluence in the parent flask or were needed for experimental protocols,
removal from the parent container proceeded as follows: Media was aspirated and the culture
was washed twice with 5 ml of serum-free MEM. Approximately 2 ml of 0.25% trypsin (Sigma)
was added to flask until cells began to detach from the culture flask, at which time ~10 ml of
serum-supplemented MEM was used to suspend the cells (proteins in the serum inactivate
trypsin). The cell suspension was centrifuged at 500 x g for 5 min. The supernatant was then
aspirated and the pellet resuspended in fresh MEM and seeded at the appropriate, experimentdependent, concentration.
Experiment 1
Overview

The first experiment was designed to screen for any neurotrophic properties of Org2766 in
the presence of a variety of compounds that are shown to be neurotoxic to Neuro-2a cells at the
doses used. The optimal dose(s) of Org2766 at which any protective effect was observed was
also determined.
Protocol

Neuro-2a cells were plated at a density of 5x10 4 cells per 35 mm tissue culture dish
(Falcon) at a volume of 1 ml in MEM plus PIS supplemented with 0.5% FBS to maximize
morphological differentiation.

A cell cytometer was used to determine cell densities under
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phase-contrast optics (Nikon).

The cultures were then grown in the incubation conditions

outlined above for 48 hrs.
At the end of the 48 hr differentiation period groups of dishes (n=5) were treated with one
of the following drug protocols:

1) a control condition containing MEM+0.5% FBS (control

media) with no drugs added; 2) 1o-5 and 1o-7 M of

vincristine sulfate, a vinca alkaloid derived

from Cantharanthus roseus, which binds to or crystallizes microtubule protein preventing
polymerization (Creasey, 1975);

3) 10-5 and 10-7 M of colchicine (Sigma), an alkaloid derived

from Co/chicum autumnale which results in the depolymerization of microtubules and also exerts
many effects on DNA (deoxy-ribonucleic acid) and RNA (ribonucleic acid) metabolism (Creasey,
1975); 4) cytochalasin D (Sigma), a microfilament depolymerizing agent; 5) the ca++_ionophore,
A23187 (Sigma). Each of these groups also received a log integer dose of Org2766 (Organon,
Intl.) ranging from 10-13 ➔ 10-e M or zero peptide.
Aliquots of Org2766 (M. W. 854) were lyophilized to ensure dosing accuracy as follows.
Org2766 was diluted in double-distilled water at a ratio of 0.854 mg peptide per 5 ml water. This
yielded a stock solution of 2x1 o-4 M.

Fifty µI of stock was then put into 1.5 ml cryo-vials

(Coming). Lyophilization of the aliquots was performed in a rotary vacuum lyophilizer (Savant).
Addition of 10 ml MEM to the lyophilized aliquots yields a 1o-e M solution. Serial dilutions were
then performed to yield the desired peptide concentrations.

No data was available on the

stability of Org2766 in the lyophilized form, but the in vitro half-life exceeds 11 days.
Cytochalasin D and A23187 were solubilized in dimethylsulfoxide (DMSO) to produce
50mM stock solutions. This stock could then be diluted in MEM/Org2766 to produce the 1o-7 or
1o-5 M concentrations, as needed. Vincristine and colchicine solutions, both of which are water
soluble, were made on an as needed basis. The drug solutions were syringe-filter sterilized
using 0.22 µm membrane filters (Corning) immediately prior to use.
At the end of the 48 hr differentiation period the media was aspirated off and the
appropriate media/drug combination added at a volume of 2 ml.

Serial samples, 100 µI in
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volume, were then taken at 8, 24 and 48 hrs. The samples were placed in microcentrifuge tubes
and spun at 500 x g for 5 min.

Ninety µI of supernatant was then drawn off and placed in

borosilicate glass test tubes (Baxter S/P) and placed on ice in preparation for the
spectrophotometric assay for lactate dehydrogenase (LDH) activity.
LDH is an enzyme which catalyzes the oxidation of lactate to pyruvate with the
concomitant reduction of nicotinamide adenine dinucleotide (NAD) to NADH (Lajtha et al., 1981).
The NADH can be quantified via an increase in absorbance at 340 nm. The rate of increase of
NADH in the sample positively correlates with LDH activity. Since the stock medium contains no
LDH, the source of any LDH detectable in the supernatant must be intracellular. There were
detectable LDH background levels under control condition. Large increases in extracellular LDH,
however, can be used as an index of cell membrane compromise or failure which is indicative of
cytotoxicity. Elevations in serum LDH activity have been shown to correlate with a variety of
injury and disease states including various liver diseases, pernicious anemia (Zimmerman &
Henry, 1979; Erickson & Morales, 1961) and myocardial infarction (Kachmar & Moss, 1976).
The change in LDH activity in the presence and absence of the cytotoxins and/or Org2766
served as the dependent variable in this experiment.
An LDH reagent kit (Sigma) containing 50 mmol/L lactate and 7 mmol/L NAD was
reconstituted with deionized water.

Four-hundred-eighty µI of reagent substrate at ambient

temperature was placed in a 1.5 ml plastic spectrophotometer cuvet. Seventy µI of sample was
added to the substrate and the cuvet was inverted five times and placed in a Beckman DU-64
spectrophotometer. Five samples could be measured each run, with the sixth position in the
spectrophotometer rack occupied by a standard containing 0.55 ml reagent alone. A Beckman
programmable spectrophotometric kinetic software module directed absorbance readings to be
made every 60 sec for a 1O min period at 340 nm. The rate of change in absorbance was
computed using only the last 5 min of the data. The reason for using only the latter 5 min was
that in most samples no change in absorbance was observed for the first 1 to 2 min. The second
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5 min period showed a much more stable and reproducible absorbance time derivative. LDH
activity was computed as follows:

(3.1)

AA = Change in absorbance per minute at 340 nm.

Where:

TV = Total reaction mixture volume [0.5 ml].

sv

= Sample volume [70 µI].

6.22 = Millimolar absorptivity of NADH at 340 nm.
LP = Lightpath length.
1000 = Converts units per ml to units per liter.
Data Analysis

Changes in LDH activity were expressed as the mean±SEM (standard error of the mean)

per cent change from the zero peptide control condition.

Statistically significant differences were

assessed via a 1-way ANOVA with a Tukey HSD follow-up (ex.= 0.05) at 8, 24 and 48 hrs.
Experiment 2
Overview

A positive neurotrophic response in Experiment 1 prompted an investigation to determine
whether the observed reduction in LDH activity was merely a function of a decrease in the rate at
which LDH was being synthesized.

To this end cell cultures pre-treated for 24 hrs in the

presence or absence of the same range of Org2766 dosages used in Experiment 1 were pulsed
for 60 min with 16 µCi 35S-Met. Total protein was determined via the method of Lowry and
differences in
protein.

de novo

synthesis were calculated as a function of scintillation counts per µg of
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Protocol

Cells were plated at a density of 5x105 cells per 35 mm tissue culture dish in MEM plus
0.5% FBS with PIS at a volume of 2 ml. The incubation environment was identical to that of
Experiment 1. At the end of the 48 hr differentiation period the culture medium was replaced
with medium containing Org2766 at log integer concentrations ranging from 10-13 ➔ 10-6 M,
plus a control condition with no peptide added (n = 7).
Twenty-four hrs later the cultures were washed three times with 1 ml of

non-serum

supplemented Met-free media taking care not to disrupt the attached cells. The cultures were
then pulsed for 60 min with 16 µCi/ml 35S-Met (TRAN 35S-LABEL, Sp. Act. > 1000 Ci/mmol, ICN
Biomedical, Inc.) in Met-free media with zero serum.

The labeled amino acid is guaranteed to

contain ~ 70% 35S-Met and ~ 15% 35S-Cys. Methionine incorporation into protein was stopped
by addition of 100% trichloroacetic acid (TCA) to a final concentration of 10% (11 O µI in this
case). The TCA causes the protein to precipitate and aggregate. A Teflon scraper was used to
loosen cell tissue from the culture dish and the solution was transferred to a glass test tube. The
dish was then washed with 5% TCA and this solution was added to the test tube. The samples
were put on ice for ~15 min to allow completion of protein precipitation.
The samples were spun at low speed and the radioactive supernatant aspirated.

The

pellets were washed by resuspending in 1. 7 ml of 5% TCA. The washing steps were repeated
three more times. Following the final centrifugation the pellet was resuspended in 0.5 ml H20.
One-half ml 1M NaOH was added and the solution mixed well in 1.5 ml polypropylene microcentrifuge tubes. Samples were then heated in a boiling water bath for ~2 min at which time the
solution would be clear indicating all the soluble components had gone

into solution.

Two

hundred µI of the sample was then used for the Lowry protein determination assay (Lowry et al.,
1951) (to determine total protein) while a second 500 µI was used for the scintillation count (to
determine the quantity of radiolabel).
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The Lowry protein assay reagents used were as follows:

A

=

2% Na 2CO3 in 0.1 N NaOH.

B

=
=
=
=

1% CuSO 4•5H 2O.

C
D
E

2% Na,K-tartrate.
50 ml A + 0.5 ml B + 0.5 ml C.
2N phenol stock reagent diluted 1 :1 with H2O.

All samples were mixed in 12 x 75 mm borosilicate glass test tubes (Baxter SIP). The
standard blank tubes contained 200 µI of 0.1 N NaOH. The protein standards used were 12.5,
25, 50, 75 and 100 µg/ml bovine serum albumin (BSA). The standard samples were mixed with
H2O to a final volume of 200 µI. For the experimental samples, 200 µI was added to each tube.
To each sample, 1 ml of reagent D was added followed by vortex mixing and the tubes were left
to stand for 10 min at room temperature. One hundred µI of reagent E was then added followed
immediately by vortex mixing.

The absorbance was read 30 min later at 750 nm using a glass

cuvette in a Gilford 250 spectrophotometer.
To calculate µg protein per ml of original sample the following conversion formulae were
used:

z

- 0. D.blank
=µg protein. per tube = 0.OD.sample
.
.D./µg protein

(3.2)

µg protein per ml original sample = z • dilution • (1 ml/vol used)

Equation (3.3) gives the total protein per ml of the original sample.

(3.3)

Another step was

needed to calculate the specific activity of the 35S-Met label as counts per min (cpm) per µg
protein. The 35S-Met is incorporated into newly synthesized protein and therefore can be used
as an indication of protein synthetic rate. Ten ml of neutralizing scintillation fluid was added to
0.5 ml of sample.

The experimental sample was replaced with 0.5 N NaOH to compute
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background disintegration counts to be entered into the final cpm as a correction factor. Two
runs were made on a Beckman LS3801 scintillation counter and the average of the two values
was used as the final value. The data were then expressed as cpm/µg protein. This number,
therefore, positively correlates with de novo protein synthesis and serves an index of synthetic
rate.
Data Analysis

The indicator of de novo protein synthesis, cpm/µg protein, was expressed as the mean ±
SEM for each group (n=7). A 1-way ANOVA with a Duncan Gap-Order follow-up was used as
the test for significant group differences (a = 0.05). The Duncan Gap Order test is a slightly less
stringent follow-up test vs. the Tukey HSD resulting in several more conditions reaching
signifigance. The means were then expressed as ± per cent change from control.
Experiment 3
Overview

The third experiment utilized time-lapse video microscopy to study recovery from the
effects of 12 hrs of treatment with 1o-7 M colchicine in the presence and absence of 1o-8 M
Org2766. This dose of peptide was shown to be optimal for the induction of neurotrophic effects
as indicated by the first two experiments. Video-microscopic images of individual cells were
captured every 5 min for a 45 min period at 8, 24 and 48 hrs following colchicine wash-out under
a variety of peptide treatment conditions including combinations of pre-, post- and co-treatment.
A control group received colchicine but no peptide treatment. The rate of change in shape of the
digitized cell contour was then calculated using area, perimeter, form factor, fractal dimensional
and Fourier analysis of the tangent angle length function measures. Comparisons of rate of
shape change were then made between peptide groups and control.
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Protocol:
Micro-incubation Environment

The Neuro-2a-C8 sub-clone was chosen for use in this study due to the complex arbors
that this cell line tends to produce.

The initial differentiation period culture conditions were

identical to those of the first two experiments with the exception that a different brand of culture
dishes were used. A description of the hardware used in maintaining the cell cultures at proper
temperature, gas and pH conditions will be followed by a description of the time-lapse video
recording, digitization and image processing hardware and software.

Experimental treatment

conditions will be described in the last section of the protocol.
The cells were grown in 35 mm (Nunc, Denmark) tissue culture dishes. This brand of dish
was chosen due to its superior optical properties relative to those of other manufacturers.

A

stock dish cover was modified to allow gassing and the changing of media conditions as follows:
The lip of the dish was ground off and a 9x15 mm opening milled in the center.

A plastic

coverslip was then cemented in place over the opening with epoxy resin. The plastic coverslip
was used as it is thinner, yielding greater passage of light vs. the plastic in the dish cover.
Two 14-gauge tubing adapters (Becton-Dickinson) were cemented into holes drilled on
opposite sides of the periphery of the dish. Polyethylene (PE) tubing, .060" O.D., was then fed
through the opening in one tubing adapter extending to the bottom of the dish. The medium
could be changed through this tube using a 3 ml syringe. A gas line was attached to the other
stub adapter through which a 10% COz'balance air mixture was fed in from a regulated supply
via a .066" I.D. PE tube. The gas first passed through a sealed glass 20 ml bottle so that flow
could be monitored by counting the number of bubbles per unit time passing through the purified
water in the bottle. A rate corresponding to ~0.5 ml min-1 was found to be sufficient to maintain
pH and 0 2 tension and keep the evaporation in the dish below 3% of the total volume following
60 hrs of continuous service.
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A 0.015" chromel-constantan thermocouple (Omega Engineering) fed through and was
cemented into another hole with epoxy resin and extended to just above the surface of the dish
bottom. The thermocouple leads led to a digital temperature bridge (Omega) whose output fed a
voltage inverter constructed for the purpose of making the thermocouple output compatible with
the direct-current proportional feedback controller (also constructed for this experiment) that
regulated the temperature of the microincubator described below. An inert coating (Thermcoat
SL, Omega) applied to the portion of the thermocouple immersed in media prevented
shortcircuiting of the thermocouple and leaching of ions into the media.
The microincubator, machined out of brass, was 106 mm in diameter which fit snugly into
the microscope stage opening.

A 38 mm diameter hole in the center of the microincubator

allowed for placement of the culture dish directly over the microscope optics. A 20:x25 mm
opening was machined into a thin brass plate attached to the bottom of the microincubator. This
made for a sufficiently large opening to view the culture and yet provided sufficient surface
contact to maximize temperature homogeneity within the dish.
The body of the microincubator was hollowed and a Nikrome heating element attached to
electrodes extended to the outer surface of the body for connection to the feedback controller. A
thin coating of high temperature silicone sealant (General Electric) in the incubator cavity
prevented electrical shortcircuit between the heating element and body of the incubator. The
cavity was filled with mineral oil which transferred heat efficiently

from the element to the

incubator body.
The temperature gradient across the dish was shown to be less than 1.5

°c with the cover

removed in bench studies. The gradient is likely less than this under experimental conditions
where the system is closed. Measuring the temperature with thermocouple placement at the
periphery ensures that the temperature at the lowest point near the dish center, where the cell of
interest resides, will be :5: 37

°c.

This system maintained temperature at 37± 0.1

variations in ambient temperature.

°c with

normal
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Several number 1 glass coverslips were placed over the center opening of the incubator
and a d.c. current was fed through a 2-watt power resistor placed on the coverslips to collapse
the temperature differential between the culture dish and room temperature. This prevented the
buildup of condensation on the inside of the cover of the culture dish which otherwise interferes
with light transmission.
The dish cover was attached to the culture immediately prior to placement in the
microincubator.

A thin strip of Parafilm was used to make a seal tight enough to allow for

maintenance of the proper gas environment and to ensure low evaporative rates, yet did not
allow positive pressure to build. A three-way neoprene valve on the gas feed between the flow
monitor bottle and the culture dish allowed the gas seal to be broken so that the media could be
withdrawn or added without building pressure differentials in the system.
Experimental Treatment

Cultures were plated at a density of 5x103 cells per dish and differentiated for 24 hrs. The
peptide and colchicine treatment protocols are summarized in Table 3.1.
Each culture could then be rapidly transferred to the laboratory where the time-lapse video
microscopy hardware was located. The standard dish cover was replaced with the special top
described in the previous section and the culture was placed in the microincubator.

The

standard medium was withdrawn and replaced with 2 ml of pre-warmed and gassed MEM
containing 0.5% FBS and 10-7 M colchicine following three washes spaced 5 min apart with
MEM alone. The current flow needed to maintain the culture at 37

°c was determined in pilot

studies prior to experimental testing. The proportional feedback controller, therefore, could be
manually overridden to bring the culture medium up to temperature following fluid replacement
without temperature overshoot.
An additional experiment (n=10) looked at the effects of 10-8 M Org2766 and 0.5% FBS
in MEM vs. control media containing no peptide.

Neither group in this experiment received
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peptide treatment during the 24 hr differentiation period. The time-lapse recording protocol was
identical to that described above.
TABLE 3.1
COLCHICINE & ORG2766 TREATMENT PROTOCOLSc

P2

Group

Control
A
B
C
D

E
F
G

Org2766
Org2766
Org2766
Org2766

Org2766b
Org2766
Org2766
Org2766

P3

Org2766
Org2766
Org2766
Org2766

a P1 = 24 hr period prior to addition of colchicine.
P2 = 12 hr colchicine treatment period.
P3 = 48 hr period following colchicine washout.
b 10-s M
c n=5 per group.

Image Acquisition

The microincubator and cell culture were placed on the stage of an inverted Nikon
Diaphot-TMD phase-contrast microscope with a 12V-50W halogen lamp. A Javelin black and
white solid-state video camera was connected to the video port on the microscope via a closedcircuit television (CCTV) adapter with 2X magnification. A 20X microscope objective was used
(Nikon) providing a total magnification of 400X.
Custom software (Ross Naheedy, LUMC Medical Informatics) directed a 5V TTL pulse
from an XT-type computer every 5 min for 10 sec to: a) a solid-state relay which switched the
microscope lamp on; b) a Sony TS-9600 Superior Performance 3/4" video cassette recorder
(VCR), switching it into Play/Record mode. Before the video signal from the camera reached the
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VCR it passed through a VTG-33 time/date generator (For-A Co. Ltd.) which superimposed the
current time and date on the final recorded image.
Following completion of acquisition of the images to KSP-60 high-resolution 3/4" video
tape (Sony), the next step was to digitize the images for processing and analysis. A DT-2861
analogue to digital (AID) framegrabber (Data Translation) installed in a 386-based AT-type
computer converted the images from analogue form on the video tape to a 512x512 pixel 8-bit
image (256 levels of grey). With the magnifications used for these experiments, each pixel was
440 nm along the x-axis and 352 nm along the y-axis. The correction for the nonsquare pixels
was made in a later processing step.

The image was stored in a buffer on the DT-2861 in a

format specific to Data Translation AID boards. A conversion program provided by DT was used
to change the OT-format to Target-lmage-File-Format-Greyscale (TIFF-G), which is a format
recognized by the image processing programs used in the later stages of image manipulation.
The 8-bit image files (1800

in toto, 262 kB per image) were then stored on a Colorado Memory

Systems cassette tape.

Image Processing

All image processing was performed on 486-based AT-type computers.

The central

processing units (CPU) in these machines have built-in mathematics co-processors, greatly
speeding run time of the arithmetic-intensive processing routines.
The image files were restored to the PC hard drive from the cassette backup tape.
Sequential processing subroutines reduced the initial 8-bit greyscale image containing a number
of cells and background noise to a 1-bit black and white image containing a single contour
representing the perimeter of the cell of interest. Repeated runs on images demonstrated a high
degree of repeatability in producing the final contour (See Appendix D, 145-147).
The images were first high-pass filtered using PhotoFinish, an image editing program (ZSoft Corp.). This software is proprietary so that the convolution kernel values are not available,
though the kernel is likely 3x3 pixels.

High-pass filtering accentuated greyscale gradients
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thereby enhancing edges.

Visual detection of the cell boundary in the x-y plane was made

easier following the filter routine (See Appendix D).
The image was then manually traced with a mouse controlled one pixel wide line of
greyscale value equal to zero within PhotoFinish. A deepest black pixel has a greyscale value of
zero, while a deepest white pixel has a value of 255. At this point of the processing the image
had a range of greyscale values with the histogram peak centered in the mid-ranges. Because
the manual tracing of the cell contour was performed with a greyscale value equal to zero, a
histogram equalization was then done to convert all pixels with values

~

1 to a value of 255.

This processing step produced an image with the contour of interest in black (greyscale equals
zero) plus any pixels that had a value of zero prior to the histogram equalization remaining black.
All other pixels then became white (greyscale equals 255). The black pixels which were not part
of the contour of interest were then erased within the editing program.

As a final step, the 8-bit

images were converted to 1-bit images greatly saving on storage space for the files.
A custom FORTRAN boundary tracking routine (DAKKRO Corp., Denver, CO) running in
batch mode using a floodfill based algorithm detects the contour boundary and outputs the
ordered x-y coordinate pairs to an ASCII (American Standard Code for Information Interchange)
text file. The enclosed area, perimeter and form factor of the closed contour was then outputted
to another ASCII file. File naming was done in such a way that the date, time and experimental
condition was encoded in a unique manner for each image, contour coordinate file and contour
geometry file. A calibration routine multiplied the x-coordinate by 1.0 and they-coordinate by 0.8
to adjust for the nonsquare pixels outputted by the framegrabber prior to running of the tracking
program.

Image Analysis

Custom software written in Borland C++ (Samuel Bowen, Argonne National Laboratory)
and running in batch mode computed the tangent angle length function

W)

and then calculated

the first 300 Fourier coefficients on ~(Q. Three hundred harmonics was determined sufficient to
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adequately describe the contour for several reasons: The smallest polygons (closed contours)
contained ~500 points, while the average was in excess of 1,000 points. Therefore, the 300th
harmonic describes details as small as ~3 pixels (1000 / 300) for the longer contours while not
dangerously over-sampling for the contours of length 500. The algorithm to calculate % error of
the Fourier series in reconstructing ~(Q as a function of the number of harmonics computed is
given below. Three hundred harmonics gives a % error of less than 3% for the most complex
contours in this investigation (see Appendix B for an example, p. 124).

In addition, in the

output of the analysis section, the higher harmonics contribute to a relatively small portion of the
variance so that even when looking at detail in the ~2 pixel range, the digitization error
contributes only modestly to the result. Since each pixel was adjusted to 440 nm per side, a
three pixel resolution translates to the ability to resolve structures as small as 1.5 µm.
The algorithm to compute % error(&) is:

(3.4)

Where:

Where:

(3.5)

Ao = The contour mean radius.

Therefore, as ~(Qseries more closely approximates the original (input) function ~(Q by
increasing the number of calculated harmonics (n), the% error(&) decreases.
The tangent angle length function ~(Q, intuitively, is the net change in angle of the tangent
to the polygon as the curve is circumnavigated from start to endpoint. The value of the function
at each point was calculated as:

¢1._J) =

arctan(

i)

(3.6)
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Where:

The output values from

~y = 0. S(yp - yp_ 1 )

(3.7)

~

(3.8)

= o.s(xp -xp_ 1)

arctan were defined within the software for all cases where either !ly or 11

x is equal to zero due to the problem of dividing by or into zero.
The Fourier expansion of W) was accomplished by the following function:

(3.9)

Where:

k)

-1 ~ LJ.'Pk
A ,I,
( 2 7if1/
An -_ -L,...
COS - n;r k=1
L

(3.10)

(3.11)

An and Bn are the Fourier coefficients and, as such, quantify the cos and sin contributions
at each harmonic. The coefficients were then combined into a single magnitude by:

(3.12)

The discussion of the intuitive meaning of Mn, first outlined in Chapter 11, is repeated here. The
detection of changes in shape, in the present work, was made via comparison of the Mn's at each
harmonic (n) as the contour changes over time. Intuitively, the value of M1 is an indication of the
circular contribution to the contour shape (any finite closed contour is going to have a very
significant value at M1 due to the 21t periodicity).
contribution, M 3 , the triangular component,
higher frequency terms (Bookstein

Similarly, M2 quantifies the elliptical

etc. The finest shape features are contained in the

et al., 1982).

The 300 Mn values for each contour were outputted to ASCII files for analysis as described
in the next section.
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Data Analysis:
i) Fourier Analysis of f'(I)

The ten ASCII files representing the sequential time-lapse recordings for a given contour
were imported into SigmaStat (Jandel Scientific) where the data was transformed in such a
manner that the 3,000 Mn values were reduced to a single number representing the first time
derivative of the shape; that is, how rapidly the contour is changing shape as a function of time
(dS/dt ). First, a custom transform computed the sum of the absolute value of the differences

between pairs of Mn values for all 300 harmonics; that is, 1time2-time 11+ 1time3-time 21............. +

Itime 10-time91.

These 300 values were then summed using the weighting scheme in Table 3.2.

TABLE 3.2
Mn WEIGHTING SCHEME

Harmonic Range

0 ➔ 10
11 ➔ 20
21 ➔ 30
31 ➔ 40
41 ➔ 50
51 ➔ 60
61 ➔ 70
71 ➔ 80
81 ➔ 90
91 ➔ 100
101 ➔ 150
151 ➔ 200
201 ➔ 250
251 ➔ 300

a

Weight via &a

Correction Factor>

1.0
1.15
1.4
1.7
1.9
2.0
2.3
2.5
2.8
3.0
3.3
3.75
4.25
5.0

6.0
5.0
4.0
3.0
2.0
1.8
1.7
1.5
1.3
1.2
1.0
0.5
0.25
0.25

defined in Eqn. 3.1. Value is proportional to % reduction in

1,

Final Weightc

6.0
5.5
5.0
4.5
4.0
3.9
3.8
3.7
3.6
3.5
3.0
2.0
1.5
1.25

by increase in harmonic#.

300

b determined from harmonic contribution to

L Mn.

Since the higher harmonics have

n=1

c

smaller absolute values, weighting is increased by a factor inversely proportional to Mn.
(interpolated) final weight = contribution to % reduction in 1, times the correction factor.

61

Therefore, the change in shape over time may be expressed as:

dS
df

=fAM
n=1

(3.13)

n

Where: Mn is weighted according to Table 3.2.
A Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test was
used for testing significant group differences (a =0.05) at each time-point (i.e. 8, 24 and 48 hrs).
This non-parametric test was used as many of the data sets proved to not be normally
distributed.

ii) Area, Perimeter and Form Factor

Area , perimeter and form factor data were imported to SigmaStat, a statistics software
package, where a custom transform converted the pixel data to (µm2} and (µm), respectively.
The change in each of these parameters was assessed as a function of time similar to that of the
Fourier magnitude data.

That is, the total

change in area, perimeter and form factor was

calculated by the output of the summation (ltime2-time 11 + ltime3-time 21 ....... + ltime10-time9 I).
The output of the summation yielded a single value for each cell characterizing the net change in
the parameter of interest. This operation was repeated for each cell in each condition at 8, 24
and 48 hrs.
The calculations for net change in area (M), perimeter (AP) and form factor (AFF) are
summarized as follows:

9

AA=~:IA+1-AI

(3.14)

t=O

9

AP= ~:IPr+1-Prl
t=O

(3.15)
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9

~FF =

L IFF,+1 - FF, I

(3.16)

t=O

Where: t = time period

0➔9,

representing steps of 5 min per period.

A Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test was
used for testing for significant group differences (a =.05) at each time-point (i.e. 8, 24 and 48
hrs).

iii) Fractal Dimension
A more complete discussion of fractal dimension is contained in Chapter II. Suffice it here
to say that the fractal dimension is an index of the scaling properties of an object. That is, in the
case of a closed polygon, how does perimeter change as a function of resolution. Resolution
can be changed by varying the length of the measuring standard. Therefore, if using every point
of a polygon to calculate perimeter yields a given value; what is the length when using every nth
point? The slope of the log-log plot of N(s) [abscissa), the number of points used to describe the
polygon, vs. L(e) [ordinate], the perimeter length given steps of length s, gives the fractal
dimension Df of the contour.
The optimal minimum number of points [N(e)]
empirically.

to describe the polygon is determined

When N(e) becomes so small that resolving power no longer can detect major

structural features of the contour the measure becomes misleading. In the case of the polygons
investigated in this work the perimeter is calculated using every

8th, 16th and 32nd point.

Again, intuitively, the slope of the log-log plot of N(E) vs. L(e) equals Df. Only every 8th, 16th
and 32nd point was used here as it was empirically determined that these contours only scale as
fractals across this small range.

Dt was calculated using custom software (Samuel Bowen, Argonne National Laboratory).
The algorithm used to compute the total change in Df was:
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AD,= ~]D,t+1 -D,tl

(3.17)

t=O

where:

(3.18)

dlo9e(1( e))
- dlo9e(e)

(3.19)

e1 = 2'(~)

(3.20)

d-

where:

where:

therefore:

Dr= 1+d

-lo [/(i+1)]
9e J(i)
d, = logj2.0)

therefore:

(3.21)

(3.22)

where:

= average stepsize
= average stepsize using every (2i)th point
i = {3,4}
L = length using every point
N = total # of points in contour

&

&i

A Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test was
used for testing for significant group differences (a =0.05) at 8, 24 and 48 hrs.

CHAPTER IV
ORG2766 AMELIORATES THE IN VITRO CYTOTOXIC EFFECTS
OF A VARIETY OF COMPOUNDS

Experiment 1
Overview

Cultured Neuro-2a cells treated with either colchicine, vincristine sulfate, cytochalasin 0
or the ca••-ionophore A23187 show a marked increase in LOH activity at 8, 24 and 48 hrs after
addition of cytotoxin to the culture media. See Table 4.1 (p. 97) for raw data. A rise in LOH
activity is interpreted as an increase in cytotoxicity. Co-treatment with Org2766 reduces LOH
activity relative to control in a dose and time-dependent fashion. The experimental results are
integrated and discussed in accordance with the findings of the protein synthesis experiment
(Chapter V).

Results and Discussion

i) 1()" 7 M Colchicine
The per cent change in LOH activity vs. Control (1 o-7 M colchicine alone) in the presence
of graded doses of Org2766 is shown in Fig. 4.1 (p. 87). The neurotrophic response is best
described by a U-function at 8, 24 and 48 hrs where a negative per cent change corresponds
with an increase in the neurotrophic effect of Org2766.

The interpretation of these results,

however, cannot stand independent of the results of the protein synthesis experiment (Fig. 5.1,

p. 101).
Figure 5.1 shows that Org2766 stimulates protein synthesis in a dose-dependent fashion
at integer log doses ranging from 10-13 ➔ 10-6 M. The peak dose for this effect was found at 10-a
M with the strength of the effect falling off to either side. Org2766 increases radiolabel into most
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bands on SOS-PAGE gel by about 40% at 10-8 M (Murry et al., 1993), so, the effect seems
general and does not appear limited to certain proteins. The reduction in LOH activity is not,
therefore, due to a decrease in synthesis of LOH.
The peak increase in protein synthesis found at 1o-8 M would maximally raise the LOH
activity index at 1o-B M with the effect dropping off to either side. An increase in LOH synthesis
of ~25%

would change the U-shaped neurotrophic function shown in Fig. 4.1 to an inverted-U

function.

An inverted-U function is consistent with that found by other investigators for the

neurotrophic action of ACTH analogues as discussed in Chapter II.
demonstrating positive neurotrophic effects has been published.

Little in vitro work

However, Org2766 does

increase the number of microtubules in large CNS axons of the snail Lymnaea stagna/is, with the
maximal effect found at 10-8 M (Muller et al., 1992). Combining this result with the Murry and
co-workers finding that 10-B M Org2766 increased radiolabel into most bands on 1-0 SOS-PAGE
gels, provides support for the argument that the U-shaped curves noted in Fig. 4.1 (and following
figures) would be changed to an inverted-U shaped function if protein synthetic effects are taken
into account. This argument is assumed in all following cytotoxin and dose conditions.
Since the protein synthesis experiment was only performed at 24 hrs it is not known if the
peptide has differential effects on de novo protein synthesis at 8 and 48 hrs. As will be seen as
the discussion progresses, neurotrophic activity, at least under some conditions, progressively
declines from 8 to 48 hrs. The degradation rate of LOH in the extracellular space of these in vitro
studies is not known. The assumption made here is that Org2766 stimulates protein synthesis at
a fairly constant rate and that the degradation of LOH lags behind synthesis resulting in a net
accumulation of LOH as a function of time. Therefore, the smaller neurotrophic effects observed
at 24 and 48 hrs under some conditions may well be due to the enhanced protein synthesis
resulting in a net accumulation of LOH.
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ii) 10-6 M Colchicine
In this condition the dose of colchicine was increased by two magnitudes.

The same

general pattern is seen here (Fig. 4.2, p. 88) as in the 1o-7 M experiment . That is, the strongest
neurotrophic effects are observed at 8 hrs with decreasing neurotrophic activity at 24 and 48
hrs.
The effect is enhanced with the greater toxic challenge presented in this condition. This is
an interesting finding as work reviewed in Chapter II suggests the neurotrophic activity of ACTH
analogues is enhanced under developmental (Frischer & Strand, 1988; Strand et al., 1989),
regenerative (Dekker et al., 1987) and degenerative (Wolterink et al., 1990a; Wolterink & Van
Ree, 1990; Wolterink et al., 1990b) conditions.

The higher dose of colchicine does induce

greater damage to the cultures as evidenced by increases in LDH activity of 48, 23 and 6% at
10-S M colchicine vs. 8, 14 and 17% at 10-7 M colchicine when comparing colchicine with no
peptide to neither colchicine nor peptide conditions (see captions of Figs. 4.1 & 4.2). This is
evidence that Org2766 exerts greater neurotrophic effects under conditions of higher toxic
challenge.
The difference in LDH activity between cytotoxin alone and zero cytotoxin controls for all
compounds tested in these and the following experiments (see Table 4.2, p. 99) tends, in
general, to decrease as time progresses. This may indicate that LDH synthetic rate is greater
than the degradative rate so that LDH is accumulating in the supernatant due to synthesis in the
zero cytotoxin condition. A similar increase in LDH levels in the peptide conditions is, therefore,
also possible due to an imbalance in synthetic and degradative rates favoring the former. In the
presence of peptide, increased protein synthesis could account for the reduced neurotrophic
effects (as assessed by LDH activity) seen under some conditions at 24 and 48 hrs.

It is

suggested here that the phenomenon is fairly general, though possible differences in cytotoxin
influences on protein synthesis are not tested in this work.
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iii) 1<r7 M Vincristine sulfate
Vincristine displayed a pattern similar to that observed in the colchicine experiments Fig.
4.3, p. 89). A U-shaped neurotrophic function is generally observed with smaller effects seen at
24 and 48 vs. 8 hrs.

Again, if LOH is accumulating in the sampled supernatant as time

progresses due to peptide induced protein synthesis, the neurotrophic activity at 24 and 48 hrs
as assessed by LOH assay might be equal to or greater than that seen at earlier times. This
would be consistent with the previously discussed evidence that peptide induced neurotrophic
activity increases proportionally with the degree of challenge.

iv) 10-5 M Vincristine sulfate

The higher VCR dosage displays a generally similar pattern to that seen at 1o-7 M (Fig.
4.4, p. 90). LOH activity, however, is lower at 48 hrs in the 1o-5 M VCR condition. This could be
due to the fact that the higher VCR dose is more toxic as indicated by a 10% increase in LOH
activity in the VCR alone condition vs. the zero VCR condition (see Captions of Figs. 4.3 & 4.4,
p. 89 & 90). Again, a greater toxic challenge correlates with a greater neurotrophic response.

v) 1<r7 M Cytocha/asin D

In the presence of 1o-7 M of the microfilament depolymerizing agent cytochalasin D (CD),
the strongest neurotrophic response is seen at 48 hrs (Fig. 4.5, p. 91) at approximately 10-6 M
Org2766 (see previous argument regarding adjustment of the shape of the function).
Interpretation of these and the previous results

is made difficult by what is possibly an

interaction between not only the dose of Org2766 and peptide synthesis, but there also may be
an interaction between cytotoxin, cytotoxin dose and protein synthesis; that is, the shape and
amplitude of the function (e.g. Fig. 4.5) varies somewhat as a function of cytotoxin and cytotoxin
dose.
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vi) 1o-6 M Cytocha/asin D

The neurotrophic response is approximately twice as strong in the high-dose CD condition
at 8 and 24, but not 48, hrs (Fig. 4.6, p. 92) vs. the lower dose CD group (Fig. 4.5). Again, this is
interpreted as an enhanced neurotrophic response in the face of a greater toxic challenge. A
possible explanation for the observation that the neurotrophic response is not as strong in the
high-dose CD group at 48 hrs is that the cultures have been so damaged by the cytotoxin that
the neurotrophic effect of the peptide is negated.

vii) 10- 7 M A23187

The steepness of the curve is greater than that seen for any of the other cytotoxins (Fig.
4.7, p. 93).

The same U-shaped function is observed at 8, 24 and 48 hrs.

The previous

argument is assumed that taking account of protein synthetic effects would change the function
into an inverted-U shape.
A23187 differs from the other cytotoxins used in these experiments in that it does not work
directly on cytoskeletal components.

However, given the importance of intracellular ca++

concentrations in the regulation of cytoskeletal dynamics e.g. (Brundage et al., 1991; Sweet et
a/., 1988), A23187 is expected to exert profound indirect effects on the cytoskeleton.

viii) 10-6 M A23187

The shape of the neurotrophic function in the presence of high-dose A23187 (Fig. 4.8, p.
94) is similar to that observed with low-dose ca++_ionophore . It is of interest that both curves
are so steep relative to that seen with the other cytotoxins studied. This may be suggestive that
the effects of the interaction between A23187 and Org2766 on protein synthesis may be
markedly different from those of the other cytotoxins. Such a line of reasoning is in line with a
great deal of experimental evidence demonstrating that ca++ is a regulator of many intracellular
processes.
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ix) Org2766
In the absence of cytotoxin, Org2766 shows a strong neurotrophic effect (Fig. 4.9 & Table
4.3, pp. 95 & 100) that does not appear time-dependent and is only weakly dose-dependent.
That is, all doses of peptide show an approximately equal response except 1o- 13 M, which is the
lowest dose used in these experiments.

This low dose of peptide also showed the weakest

effects in the cytotoxin experiments.
It is of interest that the peptide should lower LOH activity in the absence of cytotoxin in
light of the demonstrated up-regulation of protein synthesis. The fact that the dose-response
curve is essentially flat (Fig. 4.9) when the evidence indicates that protein synthesis is maximal
at 1o-B M Org2766 suggests that peak neurotrophic effects are optimal at 1o-8 M of the peptide.
The above argument could be confirmed or refuted by immuno-staining of the SOSPAGE gel (see (Murry et al., 1993)) with antibody to LOH to determine more precisely how LOH
synthesis varies as a function of treatment with Org2766; or, lysing the cells under each Org2766
condition to determine the maximal LOH response as a function of peptide dose.
The extracellular LOH detected by the assay in the control condition (zero peptide) of this
experiment is the normal background LOH.

LOH is not thought to be transported to the

extracellular space via normal transport processes though some low-level background leakage is
expected. The source of the LOH, therefore, is largely a result of cell membrane compromise.
The cytotoxins used in these experiments are thought to induce an increase in the normal
background LOH through induction of cell death or nonlethal cell membrane compromise.
Ten nanomolar Org2766 results in a 15% increase in cell number vs. control following ten
days of incubation (Fig. 4.10, p. 96).

This is likely due to an increase in survival rate vs.

proliferation rate as the Org2766/LOH experiment (Fig. 4.9) would be expected to show an
increase in LOH activity if the peptide were only increasing proliferation rate. This assumes a
linear relation between cell number and LOH release.

Taken together, the Org2766/LOH

experiment and cell proliferation study are consistent with the argument that Org2766 enhances
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cell survival at 1o-B M, a dose which shows the weakest neurotrophic effects in the presence of
cytotoxin as measured by LDH activity (see Figs. 4.1

➔

4.8).

These results strengthen the

argument that if protein synthetic effects are accounted for, the Org2766/cytotoxin experiments
would show an optimal neurotrophic effect at 1o-8 M Org2766.

CHAPTERV
ORG2766 STIMULATES PROTEIN SYNTHESIS IN
NEUROBLASTOMA CELLS IN VITRO

Overview

Org2766 stimulates protein synthesis in Neuro-2a cells in vitro in a dose-dependent
fashion. The function shape is described by an inverted-LI. See Table 5.1 (p. 102) for raw data.
This result is consistent with findings discussed in Chapter II outlining the enhancement of
protein synthesis in vivo (Schotman et al., 1972; Rudman et al., 1974) and in vitro (Reith et al.,
1974; Reith et al., 1975) by ACTH analogues. Other studies, however, fail to note an effect of
Org2766 on synthesis of neurofilament or GAP-43, which are generally taken to be indices of
neuron growth, in cultured rat spinal cord or DRG neurons (Van Der Neut et al., 1992).

Results and Discussion

Fig. 5.1 (p. 101) shows the results obtained from pulsing Neuro-2a cells for 60 min with
35 S-Met

in the presence of graded doses of Org2766 (10· 13 ➔ 1Q-6 M)

following 24 hrs of

peptide pre-treatment. Statistically significant increases in protein synthesis are observed at all
doses from 1o- 11 to 1o-6 M, with 1o.a M being an optimal dose (77% increase) for the effect.
The inverted-LI function obtained in the present work is consistent with that found in other
aspects of the neurotrophic effects of ACTH and analogues such as the enhancement of DNA,
RNA and protein synthesis by ACTH 1_24 in embryonic chick cerebral hemispheres in vitro (Daval
et al., 1983).

An inverted-LI function was also obtained when using Org2766 to enhance

performance on a passive avoidance task (Fekete & De Wied, 1982); speeding recovery from
sciatic nerve crush (De Koning et al., 1986); and, in increasing the number of neurite sprouts
following crush of rat sciatic nerve (Verhaagen et al., 1987).
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This experiment does not differentiate between transcriptional and translational effects of
the peptide. However, Bohus and De Wied showed that neither ACTH 1_10-7-L-Phe nor ACTH 1_
10-7-D-Phe altered RNA metabolism (Bohus & De Wied, 1966). The L-isomer increased while

the D-isomer decreased protein synthesis in the same study. Such a finding is consistent with a
role for ACTH in translational vs. transcriptional mechanisms.
The generality of the inverted-U shaped function across a variety of in vitro and in vivo
phenomena reviewed in Chapter II in conjunction with the present results is interesting.
Unfortunately, no direct connection can be made at this point between the protein synthetic
effects and the behavioral and neurotrophic effects observed by others. Experiments to address
these relations as well as the translation vs. transcription question are suggested in Chapter VII.

CHAPTER VI
ORG2766 SPEEDS MORPHOLOGICAL RECOVERY FROM
COLCHICINE INSULT
Experiment 1
Overview
In the first experiment the mean per cent changes in area, perimeter, form factor, fractal
dimension and shape of Neuro-2a-C8 cells were assessed at 8, 24 and 48 hrs after addition of
10-a M Org2766 or control media. The algorithms for calculating FF, D1 and dS/dt are described
in Chapter Ill.

For both Experiments 1 and 2, when cell area is discussed, the area under

consideration was the 2-D interface with the culture dish. No measurements were made in these
studies to determine cell height (z-axis) or changes in cell height. See Tables 6.1 and 6.2 (pp.
115 & 116) for raw data summary.

Results and Discussion
Mean % Change in Area
No differences in per cent change in area were noted at 8, 24 or 48 hrs (Fig. 6.1, p. 103).
Area, however, being a measure of size only, is not sensitive to a re-distribution of membrane
relative to an arbitrary landmark such as the center of cell mass.

Mean % Change in Perimeter
No differences in per cent change in perimeter were observed at any time point (Fig. 6.2,
p. 104). The perimeter measure, like area, is not a unique measure as variations or the lack of
variation in perimeter provides no information as to whether the cell is changing shape.
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Mean % Change in Form Factor

As in the previous two measures, no differences were found in the average per cent
change in form factor (Fig. 6.3, p. 105). The same caveat is noted here as above; that is, FF is
not a unique measure so provides no absolute measure regarding cell shape. Changes in cell
shape can occur with no corresponding change in FF.

Such a result, in fact, was noted in

numerous instances during data collection.

Mean % Change in Fractal Dimension

No differences in average per cent change in

o, were found between groups at 8, 24 or 48

hrs (Fig. 6.4, p. 106). The fractal dimension of the cell contours, like the above measures, is not
unique. Non-uniqueness make such measures of limited usefulness when assessing changes in
contour shape as a function of time.

dS/dt via Fourier Magnitudes

Determination of the rate of change in shape via the Fourier magnitudes (dS/dt; see
Chapter Ill) provides a true measure of cell shape which is unique and readily amenable to
statistical analysis. Any change in the tangent angle length function <j>(/) will be reflected in the
Fourier series given the calculation of a sufficient number of Fourier coefficients.
No group differences in dS/dt were found at 8, 24 or 48 hours (Fig. 6.5, p. 107). It is
concluded that there are no group differences in per cent size change (as assessed by area and
perimeter measures) nor shape change (as assessed by dS/dt) induced by 1o-S M Org2766 vs.
control in the absence of cytotoxic challenge.

Such a result is consistent with literature

discussed in Chapter II suggesting that Org2766 effects are optimized under developmental,
degenerative and regenerative conditions.
Experiment 2
Overview

Morphological recovery from 12 hrs of colchicine treatment under various Org2766
treatment protocols was assessed at 8, 24 and 48 hrs

using the same measures as in
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Experiment 1. No group differences were found using any of the peptide protocols via per cent
change in area, perimeter, FF or Of. Significant changes in dS/dt were observed for all peptide
protocols vs. control at 8, 24 and 48 hrs indicating acceleration of recovery of remodeling rate by
treatment with 1o-8 M Org2766.

The effect was noted regardless of whether Org2766 was

administered prior to, during, or after colchicine insult. See Appendix A (pp.

118➔ 123)

for a

graphical representation of the Fourier magnitudes vs. harmonic number for a particular cell
contour as a function of time. Figs. A.1 to A.3 show the first 300 harmonics while Figs. A.4 to
A.6 show the first 50 harmonics with higher resolution for the same cell.

Results and Discussion
Mean % Change in Area

No differences in per cent change in area were found at 8, 24 or 48 hrs under any of the
peptide protocols vs. control (Fig. 6.6, p. 108).

Mean % Change in Perimeter

No differences in per cent change in perimeter were found at 8, 24 or 48 hrs under any of
the peptide protocols vs. control (Fig. 6.7, p. 109).

Mean % Change in Form Factor

No differences in per cent change in form factor were found at 8, 24 or 48 hrs under any of
the peptide protocols vs. control (Fig. 6.8, p. 110).

Mean % Change in Fractal Dimension

No differences in per cent change in Of were found at 8, 24 or 48 hrs under any of the
peptide protocols vs. control (Fig. 6.9, p. 111).

dS/dt via Fourier Magnitudes

Significant increases in dS/dt between all peptide protocols and control were observed at
8, 24 and 48 hrs (Fig. 6.10, p. 112) using a Kruskal-Wallis 1-way ANOVA on ranks with a
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Student-Newman-Keuls post hoc where Q ~ 0.05. No differences between peptide groups were
found.
These results demonstrate that a true

shape measure, such as dS/dt, is sensitive to

changes in cell contour geometry which are not detected by size (area, perimeter), reformulated
size (form factor) or non-unique shape (fractal dimension) measures. In addition, since there
were no net per cent changes in cell area between peptide groups and control (Fig. 6.11, p. 113)
while dS/dt differences were in evidence, lipid membrane must be undergoing a shift in
distribution (this is an alternate way of saying that shape is changing). Such an outcome could
be accounted for within several schemes. Existing lipid can be added to or subtracted from the
outer cell membrane by endo- or exocytotic processes, respectively. Under one scenario, cell
membrane pinches off to form bi-layer vesicles which are either transferred to the extracellular
(exocytosis) or intracellular (endocytosis) domain resulting in a decrease in cell area.
Alternatively, if the vesicles initially are a part of extra- or intracellular stores, these same
processes result in an increase in cell area.
Given the results of this experiment, either the addition and/or subtraction of lipid to/from
the cell membrane occurs at levels that does not measurably affect the mean per cent change
in cell area or perimeter; or, the additive and subtractive processes, whether via endocytosis,
exocytosis or enzymatic processes, are in balance. The calculation of net per cent change in
cell area (Fig. 6.11) shows no significant difference between peptide groups and control; that is,
neither peptide nor control groups significantly differ from zero in terms of this parameter at 8, 24
or 48 hrs. The relatively large standard errors are indicative of the swing between addition and
subtraction of lipid from the membrane, resulting in a statistical net flux of zero. Consequently,
the endo- and exocytotic processes regulating cell area are in relative balance across groups.
The caution made in the initial Overview of Chapter VI applies regarding this point; that is, no
measurements of cell height (z-axis) or changes in cell height were made in these experiments.
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It is of finite probability that any change in measured cell area was a function of change in cell
height. In such a scenario, no endo-- or exocytotic processes need be invoked.
The protein synthesis experiment (Chapter V) shows that protein synthesis was increased
by 77% in the presence of 1o-8 M Org2766 relative to control. No difference in per cent change
in cell area or perimeter was found under challenge (Figs. 6.6 & 6. 7) or non-challenge (Figs. 6.1
& 6.2) conditions. Protein synthesis enhancement in the presence of colchicine was assumed
but not definite, though it is known that protein synthesis was enhanced under the non-challenge
conditions of the zero colchicine time-lapse experiment.
The relationship between cell size, as evidenced by area and perimeter, and total cell
protein is not as direct as that between total cell membrane lipid and size parameters. Cell
protein can be involved in enzymatic, regulatory and signaling processes in addition to
performing structural roles. Only the structural role was (indirectly) measured in the time-lapse
experiments. From the significant increases in dS/dt in the peptide groups relative to control in
Experiment 2 it can be inferred that the cytoskeleton was in a more dynamic state in the peptide
groups. In fact, dS/dt was not significantly different from a control group in which no colchicine
was used (Fig. 6.12, p. 114). A brief description of cytoskeletal organization and dynamics is
included below to elucidate this point.
One model of microtubule cytoskeletal dynamics in which selected microtubule polymers
undergo rapid shortening (catastrophe) and a slower re-polymerization process (rescue) is called
the dynamic instability model (Mitchison & Kirschner, 1984; Kirschner & Schulze, 1986). In this
model the overall polymer mass remains stable while individual microtubules are either growing
or shrinking with the turnover occurring at the plus-end, located towards the cell periphery. The
present results are consistent with a fairly steady overall polymer mass in a more dynamically
unstable state as assessed by dS/dt. In the dynamic instability model guanosine tri-phosphate
(GTP), when bound to the growing end of the polymer, dramatically lowers the off-rate constant
of individual subunits (Voter et al., 1991). As GTP spontaneously hydrolyzes to GDP the off-rate
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constant increases favoring microtubule depolymerization.

A polymer in such a state can grow

rapidly and then be stabilized by end interactions, but can also shrink rapidly with only small
shifts in initial conditions. It is possible that, as of yet, unidentified capping proteins are required
for long-term stabilization of individual microtubules.
A microtubule depolymerization episode can be either complete (catastrophic) or
incomplete (tempered) (Sammak et al., 1987). In vitro, microtubule polymers are in dynamic
equilibrium with monomeric a.- and ~-tubulin subunits (Sammak & Borisy, 1988) with a half-life
ranging from several to 20 min.

Direct observation of fluorescently labeled tubulin in the

fibroblast lamellum demonstrates that reorganization of the microtubule network occurs by
tempered dynamic instability (Sammak & Borisy, 1988). A large proportion of the microtubule
population remains differentially stable and displays no measurable lengthening or shortening at
least over a time scale of 15-20 min (Cassimeris et al., 1988).
Intracellular ca++ concentrations (Wang et al., 1989; Solomon, 1977; Brundage et al.,
1991) and temperature are also important regulators of microtubule dynamics. There exists an
optimal [Ca++]i for neurite elongation, above and below which growth stops or reverses (Mattson
& Kater, 1987). In general, microtubules extend along the long axis of the neurite and tend to be

evenly distributed in the plane perpendicular to that axis (Daniels, 1975).

Microfilaments,

composed of polymerized actin, are generally arranged along the outer portion of the neurite
closest to the cell membrane (Fath & Lasek, 1988). Neurofilaments display a localization similar
to that of microtubules and are thought to play an important role in the determination of neurite
caliber (Hoffman et al., 1988), though these polymers exist in a much more stable state relative
to that of microtubules and microfilaments.

Functional interactions occur between the

cytoskeletal components via microtubule-associated-proteins (MAPs) which are generally
regulated by phosphorylation state (Selden & Pollard, 1986). Others have shown that one of the
methods by which second messenger systems control the dynamic properties of the cell
cytoplasm is by regulation of the phosphorylation state of proteins which link cytoskeletal

79
components to each other and to other cell organelles (De Camilli et al., 1988). Watson has
argued effectively that neuronal function follows form in that the forces sensed by cells can
regulate cell shape. The tandem effects of external stimuli and the internal structural forces
which maintain cell shape stimulate further changes in protein synthesis/degradation, ribosome
formation, DNA/RNA synthesis, (ca++]i regulation, cell volume regulation, etc. (Watson, 1991).
The neurites extending from the

cell soma of Neuro-2a-C8 cells likely contain

microtubules existing in a dynamic state as evidenced by the non-zero dS/dt values.

The

microtubules in the soma may represent a more stable polymer population similar to those
observed by other workers e.g. (Schulze & Kirschner, 1987).

See Figs. C1 and C2 (pp. 125,

126) in Appendix C for an example of the changes in cell contour over 5 min intervals for a 25
min total time period. When a large process changes shape (see arrow in Figs. C1 & C2), the
basic skeleton of that neurite seems to be preserved in the remodeled state, at least over the
observation periods used here.

While both cells in Figs. C1 and C2 are morphologically

dynamic, the dS/dt values equal 541 and 482 for the experimental and control cell, respectively,
indicating that the cell in C1 is changing shape more rapidly. A discussion of which contour
features are changing most rapidly is included below. These particular cells were chosen as the
dS/dt values closely approximate the respective group means. The grosser features of the cell
in Fig. C1 subjectively appear to change more rapidly than the equivalent features in the control
cell.

The dS/dt values were obtained from the weighting scheme discussed previously in

Chapter Ill, which emphasizes changes in the lower harmonics.

In the control cell the finer

features subjectively appear to be changing more rapidly relative to the grosser features. These
results are consistent with the interpretation that dS/dt, using this particular weighting scheme,
tends to produce larger values when large-scale structures, described by the lower harmonics,
are in a more dynamic state relative to small-scale structures, represented by the higher
harmonics.
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The dS/dt data for the above two cells were re-evaluated using either equal weights or a
reversed scheme where the higher frequencies were emphasized (see Appendix C, Table C1, p.
136). When using the scheme emphasizing the higher harmonics (scheme C), dS/dt increased
by 7.4% (581) and 17.0% (564) relative to scheme A for the cells in Figs. C1 and C2,
respectively (see Table C2, p. 137). Such a result indicates a greater contribution to dS/dt by the
higher harmonics in the control cell.

This finding holds for all cells of Group AP3 and the

respective control group in general (see Table C3, p. 138).

Scheme B, which weights all

harmonics equally, produces an intermediate result in terms of per cent change vs. control, as to
be expected. Scheme B per cent change vs. control values are intermediate between the values
of schemes A and C for all but two P2 groups, which change very little in terms of per cent
change vs. control as the weighting scheme is modified (Table C4, pp.

139➔ 141).

This is also

consistent with the interpretation that switching progressively from scheme A to B to C makes
dS/dt progressively more sensitive to the high-frequency components of the contours.
A group EP1 cell (Fig. CS, p. 128) shows a reversed effect relative to the case discussed
above in that the per cent change vs. control increases as the weighting scheme is advanced
from A (5.6%) to B (7.3%) to C (10.0%) (Table CS, p. 142). The group EP1 cell subjectively
appears to have a more complex shape vs. the control P1 cell; therefore, the high frequencies
contribute relatively more to the shape of the experimental cell. This outcome is welcomed as it
provides support to the argument that weighting scheme A is reliably most sensitive to the
grosser features of the contours studied in this work.
The net per cent change in dS/dt vs. control as the weighting scheme is switched from
scheme A to C is shown in Table C6 (p. 143). Importantly, all of the P1 groups show a net
increase (mean

= 8.4%); all of the P2 groups, with the exception of GP2, oscillate about 0%

change (mean = 0.6%); all of the P3 groups have a decrease in per cent change vs. control
(mean = -4.5%). A single image from each of the five cells of experimental group GP2 are
shown in Figure C12 (p. 135). No obvious subjective differences are noted between the cells of
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GP2 and (for instance) AP2 (Fig. C11, p. 134). The reason as to why GP2 should differ from the
other P2 groups in terms of net per cent change vs. control when switching from scheme A to C
is not known.

The decrease seen with the P3 groups means that the experimental groups

experienced a greater rate of remodeling of the larger-scale structures relative to control at 48
hrs after colchicine wash-out.

This is not surprising as control group P3 shows an 11.5%

increase in dS/dt when switching from scheme A to C (Table C7, p. 144); whereas, AP3, for
example, shows only a 7.0% increase when switching from A to C (Table C7). A single image
of each of the five AP3 and control group P3 cells are shown in Figures C6 and C7 (pp. 129,
130), respectively.
The increase in per cent change in dS/dt vs. control seen in the P1 cells (Table C6)
indicates an increase in the remodeling rate of the finer structure relative to the control cells.
Much of this can be accounted for by the fact that three of the five control cells at P1 have few
processes and are very rounded (Fig. C8, p. 131); therefore, any change in the control cells is
represented at relatively low frequencies. This is further shown by the fact that dS/dt for control
group P1 actually decreases by 2.5% when switching from weighting scheme A to C (see Table
C7).

The group AP1 experimental cells (see Fig. C10, p. 133)

are morphologically more

differentiated vs. control, consistent with this interpretation.
The experimental groups at P2, with the exception of GP2, all demonstrate less than or
equal to 1% change vs. control when switching from scheme A to C (Table C6). This means that
the gross and fine features changed at rates whose ratio of gross to fine change is similar in
experimental vs. control group. Since dS/dt values using scheme A are significantly greater than
those of control at P2 (Table C4), the gross and fine morphological features are changing at a
greater rate vs. control and it is a difference in amount, not in kind, that is occurring. Figures C9
and C11 show a single image of each of the five cells of a control group and an experimental
group at 24 hrs after colchicine wash-out (AP2), respectively.
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The net within groups per cent change in dS/dt from P1 to P3 when switching from
weighting scheme A to C is listed in Table C7. The mean net per cent change in experimental
groups is 2.2% and in control groups is 14.0%.

This indicates that the high frequency

components of the experimental contours, representing the finer structure, recovered more
rapidly and/or received less initial damage from the colchicine treatment vs. the control
condition. By 48 hrs after colchicine wash-out, however, the control group shows the largest
within groups per cent change in dS/dt of any condition when switching from scheme A to C
(11.5%) (Table C7). This likely indicates that the experimental cells are less damaged at the
earliest time-point measured here (8 hrs after colchicine wash-out); therefore, the control cells
show a greater relative improvement from P1 to P3 because they were relatively more damaged
by the colchicine than the Org2766 treated cells.
Aside from which features are changing most rapidly, it can be stated that the
experimental groups are morphologically in a more dynamic state vs. the control group cells.
Equally as important, this difference is a consequence of treatment with 1o-a M Org2766. A
single image of each of the five cells comprising a group for a number of conditions are shown in
Figures C4 through C12 (pp.

127➔ 135).

Taking into account the cited evidence that cytoskeletal dynamics are dependent on
[Ca++]i, the phosphorylation state of MAPs, concentrations of the individual monomers and other
factors, it can be reasoned that these or some subset of these parameters were returned to or
remained within control ranges when challenged cells were treated with 1o-8 M Org2766 (Fig.
6.10). Newly published work shows the importance of ca++tcalmodulin-dependent protein kinase
II in the regulation of neurite outgrowth and growth cone motility in Neuro-2a cells, specifically
(Goshima et al., 1993). These same parameters, inferentially, remained within normal range
when unchallenged cells were exposed to Org2766 (Fig. 6.5, p. 107). Such an interpretation is
consistent with the work discussed in Chapter II that ACTH fragments and analogues display
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their strongest neurotrophic effects under developmental, degenerative and regenerative
conditions.

CHAPTER VII
SUMMARY & CONCLUSIONS

Summary

Cultured Neuro-2a cells treated with either colchicine, vincristine sulfate, cytochalasin D or
the ca++-ionophore A23187 undergo an increase in LDH activity at 8, 24 and 48 hrs after
addition of cytotoxin to the culture media. Increases in LDH activity were taken to correlate
positively with cytotoxicity. Co-treatment with Org2766 reduced LDH activity relative to control
in a dose and time-dependent manner.

Peak neurotrophic activity was, in general, seen at

roughly 10-10 and 10-6 M. A U-shaped function would describe the neurotrophic effect in these
instances. However, the literature cited in Chapter II suggests the neurotrophic effects of ACTH
and ACTH analogues are best described by an inverted-U function.
inverted-U shaped effects of Org2766 on

35 S-Met

Taking into account the

incorporation into Neuro-2a cells, it may well

be that the peak neurotrophic effect resides at the intermediate dose of 1o-a M correlating with
peak stimulation of protein synthesis. This is also consistent with in vitro work describing the
effect of Org2766 on microtubule number in snail axons (Muller et al., 1992). Consequently, 10-a
M was chosen as the best dose to use in the study to determine the effects of Org2766 on
recovery from colchicine insult as assessed by changes in cell morphology.
In Experiment 1 of the time-lapse video study no differences in mean per cent change in
area, perimeter, form factor, fractal dimension or dS/dt were observed between control and
media with 1o-8 M Org2766. Such a result is consistent with studies discussed in the Literature

Review suggesting that the neurotrophic effects of ACTH analogues are maximized
developmental, degenerative and regenerative conditions.
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under
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Morphological recovery from 12 hrs of colchicine treatment under various Org2766
treatment protocols was assessed at 8, 24 and 48 hrs

using the same measures as in

Experiment 1. No group differences were found using any of the peptide protocols via per cent
change in area, perimeter, FF or Of. Significant changes in dS/dt were observed for all peptide
protocols vs. control at 8, 24 and 48 hrs indicating acceleration of recovery of remodeling rate by
treatment with Org2766. The effect was noted regardless of whether Org2766 was administered
prior to, during, or after colchicine insult.

Conclusions

Org2766 protects against the cytotoxic effects of a variety of chemical agents, each having
a different mechanism of action. The neurotrophic effects of Org2766, therefore, appear to arise
from some general mechanism whose exact nature remains to be elucidated. The effect is not
likely due to direct pharmacological anatagonism as the LOH experiments were conducted in the
presenence of four cytotoxic compounds with differing mechanisms of action.

Similarly, as

reviewed in Chapter II, Org2766 also shows protective effects in the presence of Cisplatin, taxol
and acrylamide. The neurotrophic mechanism(s) may be related to the ability of the peptide to
stimulate protein synthesis.
The morphological studies indicate that either pre-treatment, co-treatment or posttreatment with Org2766 protects against and/or accelerates recovery from 12 hrs of colchicine
treatment as measured by dS/dt, but not by the other measures used. No differential effects on
cell contour morphology were observed in the absence of chemical insult. The three general
findings regarding significant effects of Org2766 on colchicine insulted cells were: 1) the finer
features of the cell contours were more profoundly affected relative to control at 8 hrs after
colchicine washout; 2) the gross and fine features both changed at a greater rate vs. control at
24 hrs after colchicine washout, though the ratios of gross to fine change were approximately
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equal between peptide and control;

3) the grosser features were most profoundly affected

relative to control at 48 hrs after colchicine washout.
Use of the Fourier magnitudes, derived from the Fourier analysis of the tangent angle
length function, is shown to be an effective and reliable index of shape for the class of curves
studied in this work. This method has potential for development, as the Fourier series contains
complete shape information of a quantized curve given the calculation of a sufficient number of
harmonics. Other analyses based on a more direct use of the Fourier coefficients per se might
be fruitful. The present work has analyzed a large number of complex shapes and attempted to
extract rudimentary morphological information from the Fourier magnitudes.

An exacting

analysis of well-defined simple and complex closed contours would be useful in advancing an
understanding of the precise relations between the Fourier magnitudes and individual contour
features. The use of dS/dt, as defined and developed in the present work, has shown itself to be
sensitive to shape changes for a variety of closed curves where more traditional approaches
have failed. As such, dS/dt is proposed to be a useful addition to the collection of tools available
to the morphometrician interested in the dynamic behavior of finite closed curves.
The present work demonstrates that Org2766 provides protection against the effects of a
variety of cytotoxic chemical agents possessing differing mechanisms of action for single cells in
culture.

This suggests that the peptide may not directly antagonize the effect of a given

cytotoxin, but may activate/enhance intrinsic cellular repair mechanisms. While the cells used
here were transformed cells, they retain many neuron-like properties hinting that the in vivo
neurotrophic actions of Org2766 may not require systemic mechanisms, but may work directly
on the injured tissue.
The majority of recent references pertaining to Org2766 focus on pre-clinical and clinical
studies.

Little work is being published regarding the underlying cellular (or systemic)

mechanism(s) which mediate the neurotrophic properties of this ACTH analogue. A potentially
fruitful future area of investigation would be to determine more precisely which proteins are
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being affected by Org2766 in terms of increased synthesis and/or regulation of phosphorylation
state, the second messenger system(s) involved and effects on cellular electrophysiology.
Experiments measuring incorporation of labeled uridine would determine whether Org2766
primarily affects protein synthesis at the transcriptional or translational levels would also be of
value.

FIGURES & TABLES
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TABLE 4.1
EFFECTS OF ORG 2766 ON LACTATE DEHYDROGENASE
ACTIVITY IN THE PRESENCE OF
VARIOUS CYTOTOXINS

Org 2766 [-log M]
t

0

13

12

11

10

9

8

7

6

8
24
48

120.±1
138.±1
198.±2

115.±2
123.±1*
189.±2

10-7 M Vincristine Sulfate
94.±1* 101.±3* 108.±2* 115.±3 102.±2*
119.±2* 123.±2* 134.±4 145.±2 136.±2
194.±3 188.±3 209.±4 218.±1* 212.±2*

8
24
48

106.±2
125.±2
256.±2

98.±2
124.±1
247.±3

97.±1
131.±2
248.±3

1o-& M Vincristine Sulfate
100.±4
89.±1* 95.±4* 100.±1
120.±3 125.±6 135.±2 133.±3
244.±2 254.±6 262.±3 262.±2

93.±3* 91.±1*
127.±2 123.±1
254.±4 250.±1

117.±1
173.±2*
399.±7*

110.±1
97.±2*
175.±2* 147.±3*
399.±6* 358.±6

93.±3*
111.±1
133.±2 132.±2
213.±2* 226.±2*

8
24
48

113.±1
160.±3
350.±7

100.±3*
151.±2
351.±3

108.±1
145.±2*
335.±6

1o-7 M Colchicine
104.±2* 94.±2* 117.±1
149.±2* 138.±2* 164.±2
339.±3 329.±3 369.±2

8
24
48

82.±2
130.±2
221.±5

67.±1*
128.±2
217.±4

66.±2*
122.±3
215.±1

1o-& M Colchicine
65.±3* 61.±1* 63.±2*
115.±5* 117.±1* 132.±3
193.±10*205.±3 236.±6

64.±1*
131.±3
229.±3

59.±2* 62.±1*
121.±1 124.±2
211.±4 231.±2

73.±2
74.±1
127.±1 135.±3*
273.±4* 268.±2*

80.±2*
211.±3
412.±4*

76.±2* 68.±2*
212.±4 215.±4
398.±5 406.±2

74.±2
148.±2
256.±3

76.±2
57.±2*
153.±2 123.±5*
267.±2 232.±7

8
24
48

74.±1
121.±2
314.±4

69.±3
114.±1
292.±2

65.±2*
121.±2
296.±4

1o-7 M Cytochalasin D
67.±2
80.±1
72.±2
67.±2
120.±1 121.±4 125.±6 126.±3
294.±4 277.±6* 305.±12 286.±4*

8
24
48

91.±1
222.±1
386.±4

93.±1
206.±2*
391.±8

70.±1*
179.±4*
326.±9*

1o-& M Cytochalasin D
69.±1* 74.±2* 75.±2*
180.±3* 201.±4* 225.±2
337.±2* 381.±4 412.±5*

1o-7 MA23187
8
24
48

70.±2
142.±3
247.±4

73.±1
146.±2
234±2

67.±4
141.±6
226.±4*

67.±2
55.±2* 62.±1
129.±2 126.±4* 142.±2
220.±3* 228.±2* 247.±4
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TABLE 4.1 - Continued.
Org 2766 [-log M]

t

0

13

12

11

10

9

8

7

6

10-& M A23187
8
24
48

115.±5
183.±4
357.±9

104.±3
168.±3*
329.±5*

107.±3
185.±2
358.±8

112.±3
87.±1* 102.±2
189.±2 143.±2* 180.±2
387.±2* 282.±6* 343.±7

114.±4
207.±2*
391.±6*

112.±4
91.±1*
207.±5* 178.±3
372.±2 292.±6*

* Significantly different vs. control using a 1-way ANOVA with a Tukey HSD follow-up where Q
.05.

~

Values equal lactate dehydrogenase activity x 104 as determined by spectrophotometric kinetic
analysis (mean±SEM; n=5).
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TABLE 4.2
EFFECT OF VARIOUS CYTOTOXINS ON % CHANGE IN LDH
ACTIVITY VS. CONTROL IN THE ABSENCE OF ORG2766

t

dose (M)

Vincristine

Colchicine

Cytochalasin D

A23187

8

10·7
10-'

32%*
39%*

8%*
48%*

0%
40%*

24%*
39%*

24

10-7
10-'

30%*
30%*

14%*
23%*

-10%
50%*

18%*
41%*

48

10-7
10-'

2%
10%*

17%*
6%

23%*
33%*

2%
34%*

* Significantly different from control using a 1-way ANOVA with a Tukey HSD follow-up where Q
:;:;; .05.
Values equal per cent change in LOH activity vs. control in the absence of Org2766.

100

TABLE 4.3
EFFECT OF ORG2766 VS. CONTROL ON
% CHANGE IN LDH ACTIVITY

Org 2766 [-log M]

t

13

8

24
48

4.2±2
3.5±1
-2.8±2

12

-5.8±3
-11.8±2*
-14.0±1*

11

10

-12.3±3*
-10.4±2*
-15.5±1*

-18.0±4*
-14.6±2*
-11.3±2*

9

8

7

6

-12.3±3* -12.3±2* -11.8±2 -18.0±2*
-15.7±3* -15.1±1* -4.0±2 -7.0±2
- 8.8±3* - 9.8±1* -9.7±2* -11.2±2*

* Significantly different from control using a 1-way ANOVA with a Tukey HSD follow-up where
~

.05.

Values equal per cent change in LOH activity±SEM vs. control.
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Fig. 5.1. Per cent change in 35S-Met incorporation vs. Control in the presence of graded
doses of Org2766. Each culture (n=S) was pulsed with 35 S-Met and the indicated dose of
Org2766 following 24 hrs of pre-treatment with Org2766. *Significantly different vs. Control
using a 1-way ANOVA with a Duncan follow-up where Q :s; .05.
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TABLE 5.1

EFFECTS OF ORG 2766 ON DE NOVO
PROTEIN SYNTHESIS

Org 2766 [-log M]

Control
13
12
11
10
9
8
7
6

cpm/µg protein

47.4±1.9
51.5±2.0
56.2±3.0
60.5±4.6*
63.3±1.2*
61.8±5.3*
83.7±4.5*
80.7±5.0*
75.2±5.6*

* Significantly different versus Control using a 1-way ANOVA and Duncan follow-up ( Q < .05;
n=5). Values equal mean±SEM.

103

D
5

Control
10 nM Org2766

-

4

..
ca

G)

ct

G)
C)

3

C

ca
.c

(.)

'#-

2

C

ca

G)

:iE

0 ~-------'--

8 h

24 h

48 h

Time Post- Org2766

Fig. 6.1. Average % change in area of cultured Neuro-2a-C8 cells per 5 min period 8, 24
and 48 hrs after addition of Org2766 or control media. Each group has 10 cells with 9
measurements per cell. There are no significant group differences using a Mann-Whitney U-test
where 12 ~ .05.
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Fig. 6.2. Average % change in perimeter of cultured Neuro-2a-C8 cells per 5 min period 8,
24 and 48 hrs after addition of Org2766 or control media. Each group has 10 cells with 9
measurements per cell. There are no significant group differences using a Mann-Whitney U-test
where Q ~ .05.
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Fig. 6.3. Average % change in form factor of cultured Neuro-2a-CB cells per 5 min period
8, 24 and 48 hrs after addition of Org2766 or control media. Each group has 10 cells with 9
measurements per cell. There are no significant group differences using a Mann-Whitney U-test
where Q s; .05.
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Fig. 6.4. Average % change in the fractal dimension (D,) of cultured Neuro-2a-C8 cells per
5 min period 8, 24 and 48 hrs after addition of Org2766 or control media. Each group has
10 cells with 9 measurements per cell. There are no significant group differences using a MannWhitney U-test where Q ~ .05.
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Fig. 6.5. Average rate of change in shape of cultured Neuro-2a-C8 cells per 5 min period
8, 24 and 48 hrs after addition of Org2766 or control media. Each group has 10 cells with 9
measurements per cell. The algorithm for computing dS/dt is described in Methods. There are
no significant group differences using a Mann-Whitney U-test where Q :;;; .05.
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Fig. 6.6. Average % change in area of cultured Neuro-2a-C8 cells per 5 min period 8, 24
and 48 hours after colchicine wash-out. Each group has five cells with nine measurements
per cell. *Significantly different vs. Control group (received no Org2766 at any time) using a
Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test where Q ~

.05.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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Fig. 6.7. Average% change in perimeter of cultured Neuro-2a-C8 cells per 5 min period 8,
24 and 48 hours after colchicine wash-out.
Each group has five cells with nine
measurements per cell. *Significantly different vs. Control group (received no Org2766 at any
time) using a Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test
where Q ~ .05.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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Fig. 6.8. Average % change in form factor of cultured Neuro-2a-C8 cells per 5 min period
8, 24 and 48 hours after colchicine wash-out. Each group has five cells with nine
measurements per cell. *Significantly different vs. Control group (received no Org2766 at any
time) using a Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test
where Q ~ .05.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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Fig. 6.9. Average % change in the fractal dimension (Df) of cultured Neuro-2a-C8 cells per
5 min period 8, 24 and 48 hours after colchicine wash-out. Each group has five cells with
nine measurements per cell. *Significantly different vs. Control group (received no Org2766 at
any time) using a Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc
test where Q ~ .05.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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Fig. 6.10. Average rate of change in shape of cultured Neuro-2a-C8 cells per 5 min period
8, 24 and 48 hours after colchicine wash-out (n=S). The algorithm for computing dS/dt is
described in Methods. *Significantly different vs. Control group (received no Org2766 at any
time) using a Kruskal-Wallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test
where Q :::;; .05.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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Fig. 6.11. Net % change in area of cultured Neuro-2a-C8 cells 8, 24 and 48 hours after
colchicine wash-out. There are no significant group differences.
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Fig. 6.12. Average rate of change in shape of cultured Neuro-2a-C8 cells per 5 min period

8, 24 and 48 hours after colchicine wash-out (n=S). The control group received no colchicine
in this case.
P1: 24 h period prior to addition of colchicine.
P2: 12 h colchicine treatment period.
P3: 48 h period following colchicine wash-out.
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TABLE 6.1
AVERAGE% CHANGE IN SIZE AND SHAPE PARAMETERS
AND MEAN dS/dt

Group

Perimeter

Form Factor

Mean dS/dt

t

Area

8
24
48

4.2±0.5
3.8±0.3
4.4±0.5

7.4±0.7
7.5±0.9
7.1±0.5

14.0±1.7
13.0±1.6
15.3±1.3

3.3±0.3
2.8±0.3
2.9±0.3

545.±6
529.±8
524.±7

8
24
48

4.0±0.4
3.3±0.3
4.0±0.5

7.6±1.2
8.5±1.0
7.1±0.6

13.3±2.0
15.7±1.8
13.2±1.2

3.9±0.5
3.7±0.4
3.5±0.3

538.±9
539.±7
530.±8

Dr

Org2766

Control

There are no significant between group differences for any parameters at 8, 24 or 48 hrs.
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TABLE 6.2
AVERAGE% CHANGE IN SIZE AND SHAPE PARAMETERS AND
MEAN dS/dt FOLLOWING COLCHICINE WASHOUT

t

Area

A

8
24
48

5.8±1.0
5.1±1.4
6.0±0.6

8.3±1.2
8.6±0.5
7.9±1.8

17.1±3.9
15.9±0.7
14.6±4.7

3.9±0.1
2.7±0.3
3.2±0.3

555±7*
508±9*
543±9*

8

8
24
48

6.0±0.6
4.8±1.1
5.8±0.4

10.3±1.4
7.4±1.9
6.1±0.7

18.9±1.6
17.1±4.6
12.9±1.3

4.5±0.7
3.1±0.6
2.9±0.3

567±8*
515±17*
546±9*

C

8
24
48

4.7±0.7
4.8±0.5
5.6±0.7

7.2±1.1
7.0±0.6
6.3±0.8

15.2±2.3
12.3±1.4
12.5±1.7

3.4±0.4
3.8±0.3
4.3±1.1

544±9*
533±5*
542±4*

D

8
24
48

5.3±1.3
3.8±0.5
5.3±0.9

8.0±1.8
7.2±1.2
8.3±1.4

15.7±4.0
15.6±2.0
16.1±2.7

4.1±0.4
2.7±0.4
3.0±0.5

535±10*
528±8*
518±14*

E

8
24
48

5.0±0.6
5.6±1.0
4.4±0.6

8.2±2.1
8.0±1.5
8.0±1.9

18.9±4.5
15.6±2.4
16.7±3.9

3.4±0.7
3.2±0.3
2.8±0.4

534±7*
519±20*
544±12*

F

8
24
48

5.0±0.5
5.2±0.4
5.1±0.8

9.9±1.9
7.9±0.7
6.9±1.0

22.0±5.0
16.8±1.6
16.4±2.2

4.0±0.9
3.8±0.5
3.1±0.4

540±8*
546±9*
550±3*

G

8
24
48

4.3±0.9
3.4±0.7
2.9±1.0

8.7±1.0
4.6±0.5
7.5±1.2

17.7±1.6
9.8±1.3
15.9±2.2

4.1±0.5
2.6±0.5
3.2±0.3

552±6*
520±14*
526±19*

Control 8

3.4±0.5
3.7±0.6
4.9±0.5

8.1±1.7
7.4±1.4
6.8±0.7

14.7±2.6
13.2±2.3
13.3±2.1

2.9±0.7
3.6±0.5
3.1±0.5

483±31
454±25
488±8

Group

24
48

Perimeter

Form Factor

Df

Mean dS/dt

* Significantly different from control using a Kruskal-Wallis 1-way ANOVA on ranks with a
Student-Newman-Keuls post hoc where p

~

.05.
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APPENDIX A
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Fig. A.1. Fourier magnitudes (M) of the first 300 harmonics of the superimposed contour.

These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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Fig. A.2. Fourier magnitudes (M) of the first 300 harmonics of the superimposed contour.
These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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Fig. A.3. Fourier magnitudes (M) of the first 300 harmonics of the superimposed contour.
These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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Fig. A.4. Fourier magnitudes (M) of the first 50 harmonics of the superimposed contour.
These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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Fig. A.5. Fourier magnitudes (M) of the first 50 harmonics of the superimposed contour.
These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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Fig. A.6. Fourier magnitudes (M) of the first 50 harmonics of the superimposed contour.
These contours are actual data from Group A 48 hrs after colchicine washout. Temporal spacing
between contours equals 5 min.
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APPENDIX B
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Fig. B. Reduction in per cent error (&) with the calculation of increasing number of
hannonics. See Chapter Ill for a discussion of s and the corresponding algorithm.
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APPENDIXC

Fig. C1. Change in cell shape as a function of time. Time progresses from left to right and
down in 5 min intervals. This Group A cell was recorded 48 hrs after colchicine washout. dSldt
is equal to 541, where the group mean equals 543. Note shape change of one particular process
indicated by arrow.
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Fig. C2. Change in cell shape as a function of time. Time progresses from left to right and
down in 5 min intervals. This control cell was recorded 48 hrs after colchicine washout. dS/dt is
equal to 482, where the group mean equals 488. Note shape change of one particular process
indicated by arrow.
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Fig. C4. Change in cell shape as a function of time. Time progresses from left to right and
down in 5 min intervals. This control cell was recorded 8 hrs after colchicine washout. See text
in Chapter VI for discussion.

128

Fig. CS. Change in cell shape as a function of time. Time progresses from left to right and
down in 5 min intervals. This Group E cell was recorded 8 hrs after colchicine washout. See
text in Chapter VI for discussion.
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Fig. C6. A single time-lapse image of each of the five cells of Group AP3.

130

Fig. C7. A single time-lapse image of each of the five cells of control Group at P3.
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Fig. CS. A single time-lapse image of each of the five cells of control Group at P1.
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Fig. C9. A single time-lapse image of each of the five cells of control Group at P2.
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Fig. C10. A single time-lapse image of each of the five cells of Group AP1.
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Fig. C11. A single time-lapse image of each of the five cells of Group AP2.
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Fig. C12. A single time-lapse image of each of the five cells of Group GP2.
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TABLE C1
MODIFIED Mn WEIGHTING SCHEMES

Harmonic Range

0 ➔

11
21
31
41
51

➔
➔

10
20
30
40
50
60

61

➔

70

71
81
91
101
151
201
251

➔

➔
➔
➔

80
90
➔ 100
➔ 150
➔ 200
➔ 250
➔ 300
➔

6.0
5.5
5.0
4.5
4.0
3.9
3.8
3.7
3.6
3.5
3.0
2.0
1.5
1.25

1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0
1.0

1.25
1.5
2.0
3.0
3.5
3.6
3.7
3.8
3.9
4.0
4.5

5.0
5.5
6.0

These are the same weights used in the computation of dS/dt in Chapter VI.
All values are equally weighted.
c Weights are reversed so that the higher harmonics contribute to a greater extent vs. A in the
determination of dS/dt.
a
b
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TABLE C2
dS/dt AS A FUNCTION OF MODIFICATIONS IN
WEIGHTING SCHEME *
Weighting
scheme

dS/dt

%

t

vs. Control

A

Cell AP3
Control Cell

541
482

12.2%

8

Cell AP3
Control Cell

155
144

7.6%

C

Cell AP3
Control Cell

581
564

3.0%

* dS/dt values in one experimental and one control cell as a function of change in the weighting
scheme.
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TABLEC3
dS/dt AS A FUNCTION OF MODIFICATIONS IN
WEIGHTING SCHEME
Weighting
scheme

dS/dt

%

t

vs. Control

A

GroupAP3
Control

543±9*
488±7

B

GroupAP3
Control

155±3
141±4

9.9%

C

GroupAP3
Control

581±12
544±25

6.8%

11.3%

* Significantly different vs. control using a Mann-Whitney Rank Sum test (Q ~ .05). Values equal
mean±SEM.
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TABLE C4
dS/dt AS A FUNCTION OF MODIFICATIONS IN
WEIGHTING SCHEME

Group

A

Period

Weighting
scheme

P1

A

11.9%
10.8%
11.0%

543±9*
155±3
581±12

11.3%
9.9%
6.8%

567±8*
158±2
578±9

17.4%
20.6%
22.7%

515±17*
147±5
549±19

13.4%
13.9%
14.1%

546±9*
155±2
580±5

11.9%
9.9%
6.6%

543±9*
154±3
575±14

12.4%
17.6%
22.1%

C

533±5*
151±2
561±11

17.4%
17.1%
16.6%

A
B
C

542±4*
153±2
571±8

11.1%
8.5%
5.0%

C
A

B
C

P1

A

B
C

P2

A

B
C
P3

A

B
C
C

P1

A

B
C
P2

A

B
P3

vs. Control

508±9*
143±3
534±15

A

B

B

t

14.9%
20.6%
24.6%

C

P3

%

555±7*
158±2
587±9

B

P2

dS/dt
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TABLE C4 -Continued.

Group

D

Period

Weighting
scheme

P1

A
B

C
P2

A
B

C
P3

A
B

C
E

P1

A
B

C

P2

A
B

C

P3

A
B

C
F

P1

A
B

C

P2

A
B

C

P3

A
B

C

dS/dt

%

t

vs. Control

535±10*
150±3
554±18

10.8%
14.5%
17.6%

528±8*
150±2
561±8

16.3%
16.2%
16.6%

518±14*
147±3
552±9

6.1%
4.2%
1.5%

534±7*
150±2
560±4

10.6%
14.5%
18.9%

519±20*
147±5
545±21

14.3%
13.9%
13.3%

544±12*
156±3
590±16

11.5%
10.6%
8.5%

540±8*
153±2
567±8

11.8%
16.8%
20.4%

546±9*
154±3
574±11

20.2%
19.4%
19.3%

550±3*
155±1
578±8

12.7%
9.9%
6.2%
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TABLE C4- Continued.

Group

G

Control

Period

Weighting
scheme

dS/dt

%

t

vs. Control

P1

A
B
C

553±6*
157±3
587±19

14.5%
19.8%
24.6%

P2

A
B
C

520±14*
152±4
582±15

14.5%
17.8%
21.0%

P3

A
B
C

526±19*
152±5
577±18

7.8%
7.8%
6.0%

P1

A
B
C

483±31
131±11
471±45

P2

A
B
C

454±25
129±7
481±31

P3

A
B
C

488±7
141±4
544±25

* Significantly different vs. Control group (received no Org2766 at any time) using a KruskalWallis 1-way ANOVA on ranks with a Student-Newman-Keuls post hoc test where Q ~ .05.
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TABLE CS
dS/dt AS A FUNCTION OF MODIFICATIONS IN
WEIGHTING SCHEME *

Weighting
scheme

dS/dt

%

t

vs. Control

A

Cell EP1
Control Cell

563
533

5.6%

B

Cell EP1
Control Cell

162
151

7.3%

C

Cell EP1
Control Cell

618
562

10.0%

* dS/dt values in one experimental and one control cell as a function of change in the weighting
scheme.
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TABLE C6
EFFECTS OF WEIGHT MODIFICATIONS

Net % Change vs. Control When
Switching from Scheme A to C
Group
AP1 8
BP1
CP1
DP1
EP1
FP1
GP1
mean
AP2
BP2
CP2
DP2
EP2
FP2
GP2
mean
AP3
BP3
CP3
DP3
EP3
FP3
GP3
mean

% Change

9.7
5.3
9.7
6.8

8.3
8.6

10.1
8.4
-0.9

0.7
-0.8

0.3
-1.0
-0.9
6.5
0.6
-4.5
-5.3
-6.1
-4.6

-3.0
-6.5
-1.8
-4.5

a These values were obtained by calculating the difference between the %
Control values using scheme C vs. scheme A listed in Table C4.

t

in dS/dt vs.

144
TABLE C7
EFFECTS OF WEIGHT MODIFICATIONS

Net % Change in dS/dt Within Groups
When Switching from Scheme A to ca
Net% Change
P1 ➔ p3b

Group

% Changea

AP1
AP2
AP3

5.8
5.1
7.0

1.2

BP1
BP2
BP3

1.9
6.6
6.2

4.3

CP1
CP2
CP3

5.9
5.3
5.4

-0.5

DP1
DP2
DP3

3.6
6.2
6.6

3.0

EP1
EP2
EP3

4.9
5.0
8.5

3.6

FP1
FP2
FP3

5.0
5.1
5.1

0.1

GP1
GP2
GP3

6.1
11.9
9.7

3.6

Control P1
P2
P3

-2.5
5.9
11.5

mean

2.2
14.0

a These values were obtained by calculating the within groups % increase in dS/dt when
switching from weighting scheme A to C.

b These values were obtained by subtracting the within groups % increase in dS/dt when
switching from weighting scheme A to C (seen in middle column) at P1 from P3.
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Legend Figures D1 & D2

A: Original 8-bit images.

B: Image in A following high-pass filter.
C: Tracing of image in B yielding a 1-bit image.
D: The (x,y) co-ordinate points of the contour of the image in C, obtained from the output of the

boundary tracking routine, were stored in an ASCII file for analysis by the various
morphometric routines. The reconstruction of the image from these co-ordinate points is
shown in D. The reflection of the image is due to a difference in the designation of point (0,0)
between the original image and the boundary-tracked image. Note that all analyses are
reflection invariant. The flattening of the reconstructed image at this stage is due to the
correction for the non-square pixels in the light sensing chip of the video camera. The slight
rounding of the smallest detail is a function of the reconstructed image being printed out from
a Postscript format vs. the pixel for pixel print format of the top three images.
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A

B

C

D

Fig. D1. See legend.
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A

B

C

D

Fig. D2. See legend.
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